

IBEX: An open and extensible method for high content multiplex imaging of diverse tissues

Andrea J. Radtke^{1,13,*}, Colin J. Chu^{2,3,13}, Ziv Yaniv⁴, Li Yao⁵, James Marr⁶, Rebecca T. Beuschel¹, Hiroshi Ichise², Anita Gola^{2,7}, Juraj Kabat⁸, Bradley Lowekamp⁴, Emily Speranza^{2,9}, Joshua Croteau¹⁰, Nishant Thakur², Danny Jonigk¹¹, Jeremy Davis¹², Jonathan M. Hernandez¹², and Ronald N. Germain^{1,2,*}

¹Center for Advanced Tissue Imaging, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA

²Lymphocyte Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA

³Translational Health Sciences, Bristol Medical School, University of Bristol, United Kingdom

⁴Bioinformatics and Computational Bioscience Branch, NIAID, NIH, Bethesda, MD, USA

⁵Howard Hughes Medical Institute, Chevy Chase, MD, USA

⁶Leica Microsystems Inc., Wetzlar, Germany

⁷Howard Hughes Medical Institute, Robin Neustein Laboratory of Mammalian Cell Biology and Development, The Rockefeller University, New York, NY, USA

⁸Biological Imaging Section, Research Technologies Branch, NIAID, NIH, Bethesda, MD, USA

⁹Innate Immunity and Pathogenesis Section, Laboratory of Virology, NIAID, NIH, Hamilton, MT, USA

¹⁰Department of Business Development, BioLegend, Inc., San Diego, CA, USA

¹¹Institute of Pathology, Hannover Medical School, Hannover, Germany, Member of the German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH)

¹²Surgical Oncology Program, Metastasis Biology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA

¹³Co-first authors

*Co-corresponding authors: Andrea J. Radtke (andrea.radtke@nih.gov); Ronald N. Germain, (rgermain@niaid.nih.gov)

Andrea J. Radtke: 0000-0003-4379-8967, Colin J. Chu: 0000-0003-2088-8310, Ziv Yaniv: 0000-0003-0315-7727, Li Yao: 0000-0003-2390-083X, James Marr: 0000-0001-8353-1429, Rebecca T. Beuschel: 0000-0002-3882-457X, Hiroshi Ichise: 0000-0002-5187-810X, Anita Gola: 0000-0003-1431-1398, Juraj Kabat: 0000-0001-8636-542X, Bradley Lowekamp: 0000-0002-4579-5738, Emily Speranza: 0000-0003-0666-4804, Joshua Croteau: 0000-0002-8142-0482, Nishant Thakur: 0000-0003-3699-0037, Jeremy Davis: 0000-0002-6334-6936, and Ronald N. Germain: 0000-0003-1495-9143.

Abstract

High content imaging is needed to catalogue the variety of cellular phenotypes and multi-cellular ecosystems present in metazoan tissues. We recently developed Iterative Bleaching Extends multi-pleXity (IBEX), an iterative immunolabeling and chemical bleaching method that enables multiplexed imaging (>65 parameters) in diverse tissues, including human organs relevant for international consortia efforts. IBEX is compatible with over 250 commercially available antibodies, 16 unique fluorophores, and can be easily adopted to different imaging platforms using slides and non-proprietary imaging chambers. The overall protocol consists of iterative cycles of antibody labelling, imaging, and chemical bleaching that can be completed at relatively low cost in 2-5 days by biologists with basic laboratory skills. To support widespread adoption, we provide extensive details on tissue processing, curated lists of validated antibodies, and tissue-specific panels for multiplex imaging. Furthermore, instructions are included on how to automate the method using competitively priced instruments and reagents. Finally, we present a software solution for image alignment that can be executed by individuals without programming experience using open source software and freeware. In summary, IBEX is an open and versatile method that can be readily implemented by academic laboratories and scaled to achieve high content mapping of diverse tissues in support of a Human Reference Atlas or other such applications.

Introduction

Ambitious efforts across multiple consortia, including the Human Cell Atlas (HCA)¹ and Human Biomolecular Atlas Program (HuBMAP)², aim to characterize all cell types in the human body, with the ultimate goal of creating a Human Reference Atlas. While it is impossible to precisely estimate the number of cell types present in the human body, nor the complete list of biomarkers needed to define these unique entities, a recent report identified 1,534 anatomical structures, 622 cell types, and 2,154 biomarkers (632 of which were proteins) in 11 human organs³. To provide a spatial context for these complex data, the field needs high content methods that capture the *in situ* biology of diverse tissues with sufficient coverage depth. Beyond supporting efforts to build a comprehensive map of healthy human tissues, high content imaging is critical for understanding tumor-immune interactions as well as the histopathology of disease.

To this end, several multiplexed antibody-based imaging methods have been developed⁴⁻¹⁵ and reviewed¹⁶⁻¹⁸. Furthermore, a detailed comparison of these methods can be found in a recent commentary authored by domain experts in the field of spatial proteomics¹⁹. The majority of these existing methods generate high dimensional datasets through an iterative multistep process (a cycle) that includes: i) immunolabeling with antibodies, ii) image acquisition, and iii) fluorophore inactivation or antibody/chromogen removal. In addition to fluorophore-labelled antibodies, alternative methods such as immunostaining with signal amplification by exchange reaction (Immuno-SABER)¹³ and co-detection by indexing (CODEX)¹² employ antibody DNA-barcoding with complementary fluorescent oligonucleotides to collect multiplexed imaging data. Here, fluorescent oligonucleotides are rapidly hybridized and dehybridized to visualize multiple biomarkers *in situ*. In contrast to these cyclic imaging methods, technologies utilizing metal-conjugated antibodies, such as multiplexed ion beam imaging (MIBI)¹⁴ and imaging mass cytometry (IMC)¹⁵, probe >40 markers without iterative antibody labeling or removal steps. Although commercialization of CODEX, MIBI, and IMC have enabled deep spatial profiling of tissue samples from large clinical cohorts²⁰⁻²², these methods are limited to specialized instruments, proprietary reagents, and, for mass spectrometry (MS)-based methods, may require highly trained engineering staff for instrument support.

For these reasons, we developed Iterative Bleaching Extends multi-pleXity (IBEX)²³, a high content imaging method that can be implemented by scientists with basic laboratory skills at relatively low cost. Using commercially available reagents and microscopes, IBEX has been used to spatially characterize complex phenotypes in tissues from experimental animal models²⁴ as well as clinically relevant human samples²³. Because antibody validation and panel development can be costly in terms of time and capital¹⁹, we provide curated lists of

antibodies as well as example panels for several tissues. The majority of these resources are optimized for a fixed frozen method of tissue preservation that overcomes the need for antigen retrieval; however, we demonstrate how IBEX can be adopted to formalin-fixed, paraffin embedded (FFPE) tissues. While not documented here, we have previously shown that the basic IBEX workflow enables multiplexed imaging of heavily fixed tissues using Opal fluorophores and is compatible with commercially available oligonucleotide-conjugated antibodies²³. In this paper, we provide extensive details and representative data for execution of the IBEX protocol along with instructions on how to automate and accelerate data collection using a cost-effective fluidics device and widefield microscope. We additionally provide guidelines for the proper orientation and embedding of tissues to standardize data interpretation across specimens. To facilitate widespread adoption, we present a software solution for image alignment based on a simplified open source interface to the Insight Toolkit (SimpleITK)^{25,26} that can be used by laboratory scientists without programming experience.

Development of the protocol

IBEX expands on earlier work demonstrating the feasibility of using borohydride derivatives to bleach fluorescently conjugated antibodies for multiplex imaging^{9,27,28}. Bolognesi *et al.* and others have provided details on the chemistry, fluorophore inactivation, and proteolytic properties of sodium borohydride under their user-defined experimental conditions^{9,27-33}. For the manual IBEX method described here, we consistently found that 15 minutes of exposure to 1 mg/ml of Lithium Borohydride (LiBH₄), a strong reducing agent³⁴, eliminated fluorescence signal from the following dyes: Pacific Blue, Alexa Fluor (AF)488, AF532, Phycoerythrin (PE), AF555, eFluor (eF)570, iFluor (iF)594, AF647, eF660, AF680, AF700, and AF750. Other fluorophores (Fluorescein isothiocyanate (FITC)) required a longer incubation time (<30 minutes) or bleaching in the presence of light (Brilliant Violet (BV) BV421 and BV510) for signal loss. Finally, certain fluorophores (Hoechst, JOJO-1, AF594, eF615) maintained their signal over multiple bleaching and imaging cycles (Table S1). The new automated IBEX protocol described in this report requires 0.5 mg/ml of LiBH₄ treatment for 10 minutes or, in some cases, 20 minutes under constant flow (120 μ l/minute) for fluorophore inactivation. The continual exchange of fresh 0.5 mg/ml of LiBH₄ (automated), as opposed to a one-time application of 1 mg/ml (manual), enables efficient bleaching at a reduced concentration of LiBH₄ while preventing excessive bubble formation within the closed bath chamber, an issue not encountered with the manual method.

Tissue-specific panels are designed using antibodies conjugated to LiBH₄-sensitive dyes with a LiBH₄-resistant dye (usually Hoechst) serving as a fiducial for image alignment across iterative cycles. In our original publication we demonstrated that LiBH₄ acts by eliminating fluorescence signal by fluorophore inactivation and not antibody removal²³. This feature allows for the inclusion of unconjugated primary antibodies in earlier cycles and amplification with fluorescently conjugated secondary antibodies in later cycles as outlined in the automated IBEX panels deposited here (Table S2). While both IBEX methods are compatible with indirect immunolabeling, we prefer to use directly labeled antibodies from vendors or conjugated in house using commercial kits. In addition to the points raised by Hickey and colleagues¹⁹, we recommend purchasing >100 μ g of antibody in a suitable format for conjugation; concentration of 1 mg/ml or greater in a buffer without carrier proteins or additives. For panels requiring multiple unconjugated antibodies, we advise placing these antibodies in earlier cycles to avoid unwanted detection by the secondary antibody with directly conjugated antibodies generated in the same host. Furthermore, primary antibodies must be raised in different hosts (rabbit, goat, and rat) versus multiple clones from the same host (3 rabbit clones) when using unconjugated versions with secondary antibody detection. Lastly, the selected secondary antibodies should be highly cross-adsorbed against antibodies from other host species. Here, we provide additional details for pairing antibodies and fluorophores for optimal imaging using manual and automated IBEX methods (Tables S3). Importantly, the number of parameters that can be imaged per IBEX cycle is dependent on several variables including microscope configuration, tissue autofluorescence, availability of conjugated antibodies, and overall panel design (Tables S2-S3).

The resulting method, IBEX, provides an efficient means for evaluating the spatial landscape of diverse tissues by offering: i) an adhesive that securely attaches tissues to the slide/coverslip surface over multiple fluid exchanges, ii) an abbreviated antibody labelling step to shorten the overall protocol, and iii) an open source image registration workflow. Using the tissue adhesive chrome gelatin alum, IBEX can be performed on the most delicate of tissues without tissue loss or degradation for up to 20 cycles in some cases²³. Antibody labelling is accelerated using a specialized non-heating microwave for the manual IBEX method (30-45 minutes per cycle) and microscope stage heater at 37°C for the automated IBEX method (1 hour per cycle). The SimpleITK workflow provides registration of images acquired as a 3D tissue stack (manual IBEX) or single 2D z-slice (automated IBEX). We document an easy-to-use Imaris XTension (Bitplane) for registration that can be executed by individuals without programming experience. As an additional resource, an overview of costs is provided to aid potential users in writing an instrument grant application or adopting IBEX in their laboratory (Table S4).

Overview of the protocol

Here, we provide detailed instructions for obtaining high content images from a wide range of tissues using human material as exemplars (Figure 1). The protocol outlines tissue grossing (Steps 1-2), tissue processing (Steps 3-7), manual (Steps 8-38) or automated (Steps 39-77) IBEX imaging, and image alignment with SimpleITK (Steps 78-90). The overall workflow consists of 1) specimen preparation and preservation, 2) IBEX imaging, and 3) image processing that can be executed in 2-5 days or paused after each stage.

Applications

The target audience for IBEX ranges from academic laboratories desiring an affordable method for highly multiplexed imaging to commercial entities seeking a scalable workflow for characterizing clinical samples. Published studies have evaluated the distribution of immune cells in the livers of prime and target vaccinated animals²⁴ and visualized diverse stromal populations in human and mouse tissues using multiple markers²³. Ongoing studies include, but are not limited to, assessing the tumor microenvironment of clinical samples and profiling unique epithelial cell populations present within the human thymus. The additional advancements described here—automation and an easy-to-use image alignment software package—make it an attractive method to gain additional insight into the cellular ecosystems of diverse tissues.

Experimental design

Tissue processing

In general, sample collection informed by anatomical landmarks (e.g., right axillary lymph node) and histological features (e.g. spatially invariant vasculature) is critical for proper specimen evaluation³⁵. For tissue mapping efforts in support of a Human Reference Atlas, precise anatomical locations are required to integrate molecular and spatial data across individuals using a common coordinate framework (CCF)^{2,36}. For these reasons, it is important to record these details and, if possible, discuss with the contributing surgeon, radiologist, and pathologist if unclear. Because the process of autolysis begins immediately after surgical removal of tissues or biopsy, we recommend placing specimens in fixative as soon as possible to prevent tissue degradation and thus preserve immunoreactivity and cytomorphology^{35,37}. The most standard fixative, 10% neutral buffered formalin (4% formaldehyde), fixes tissue at a rate of 1-2 mm per hour at room temperature^{37,38}. To ensure appropriate fixation, tissues should be cut into thin sections (less than 3-5 mm thick), placed in 15-20 fold the volume of fresh fixative, and incubated for a sufficient length of time (12-20 hours)^{37,38}. IBEX is compatible with FFPE samples and detailed protocols for the preparation of such samples are outlined elsewhere³⁸. To overcome the technical challenges posed by FFPE samples including epitope loss, the need for antigen retrieval, and high autofluorescence, we utilize a fixative

with ~1% (vol/vol) formaldehyde and a gentle detergent. Following fixation, samples are immersed in 30% (wt/vol) sucrose for cryoprotection. Using this fixed frozen method, our laboratory has performed multiplexed imaging on a wide range of murine and human tissues³⁹⁻⁴⁶. Beyond excellent tissue preservation, this protocol significantly reduces autofluorescence by lysing red blood cells and reducing lipid-containing pigments. Prior to tissue embedding, it is important to properly orient specimens using guidelines established by surgical pathologists^{35,37}. We provide detailed descriptions in the Procedure section for optimal handling of the human bowel, skin, lymph node, and wedge resections (liver, kidney, spleen) as examples (Box 1). We are presently finalizing panels and developing workflows for a greater range of tissues including human and mouse lung, thymus, and various tumors, with our current data showing all these tissues to be compatible with the IBEX protocol.

Antibody validation and panel design

A central tenet of IBEX, and other such methods^{4-9,11-15}, is the collection of reproducible multiplexed imaging data using antibodies specific for their intended targets. Recently, members of multiple tissue-mapping consortia including the HCA¹, HuBMAP², Human Tumor Atlas Network (HTAN)⁴⁷, and Human Protein Atlas⁴⁸, established guidelines for multiplexed antibody-based imaging methods¹⁹. We refer the reader to this work as it documents how to properly validate antibodies, build and test multiplexed antibody panels, conjugate custom antibody reagents, and overcome tissue autofluorescence. Furthermore, this work provides lists of antibody clones (>400 human; >90 mouse) that have been benchmarked by different users across distinct imaging platforms, including IBEX. An additional resource for qualifying multiplexed imaging panels can be found in a detailed protocol authored by Du and colleagues using tissue-based cyclic immunofluorescence (t-CyCIF)⁴⁹. Of note, this work provides several considerations for characterizing antibody immunolabeling at the pixel-, cell-, and tissue-level and offers guidelines for minimizing artifacts arising from iterative imaging methods. Beyond these technical considerations, skillful panel design requires clarity on the scientific questions to be addressed as well as knowledge of the anatomical structures and cell types present within a given organ. The anatomical structures, cell types, plus biomarkers (ASCT+B) tables— assembled by more than 50 domain experts—are a valuable resource for understanding the tissue microanatomy of 11 human organs (Bone marrow and blood, Brain, Heart, Large intestine, Kidney, Lung, Lymph node, Skin, Spleen, Thymus, Vasculature) with more in the pipeline³. Furthermore, one can explore these data with a state-of-the-art visualization tool, aiding in the selection of cell-specific protein biomarkers (BP) to target for multiplexed imaging (<https://hubmapconsortium.github.io/ccf-asct-reporter/>).

Besides these resources, we provide antibodies, multiplexed tissue panels, and several IBEX-specific guidelines to aid in high quality data generation (Tables S1-S3). Because immunolabeling can vary across tissues, fixation conditions, and the imaging system employed, we recommend careful titration of all antibodies prior to IBEX imaging. Additionally, it is important to test whether novel antibodies are sensitive to LiBH₄ before adding them to established multi-cycle panels. This can be determined by comparing immunolabeling in serial sections with or without LiBH₄ pre-treatment. For evaluating potential epitope loss resulting from steric hindrance, we compare the spatial distribution patterns of antibody panels acquired serially to ones acquired iteratively via IBEX as we have previously shown²³. In rare instances, if a particular antibody is thought to be impacted by LiBH₄ exposure or cycle order, the affected antibody is moved to an earlier panel. To elaborate on the effect of cycle number on antigenicity, antibodies directed against CD106 (RRID: AB_314561), Chromogranin A (RRID: AB_2892553), and DCAMKL1 (RRID: AB_873537) performed better in cycle 1 than in cycles 10, 7, and 5, respectively, in a 48-plex human thymus imaging panel (unpublished work). This issue impacts <2% of IBEX characterized antibodies versus the 12%⁶ to 15-20%⁸ of antibodies shown to be affected by cycle number in methods employing hydrogen peroxide (H₂O₂) as a fluorophore inactivation agent. However, we have observed diminished signal intensity with AF700-conjugated antibodies placed in later cycles (after cycle 4) as opposed to the same clone conjugated to other fluorophores. This, coupled with the limited availability of AF700-conjugated antibodies, reduces the number of parameters that can be robustly imaged over

successive cycles. Given the importance of fluorophore conjugate on antibody performance, we provide guidelines for antibody-fluorophore pairing specific to manual and automated modes of IBEX (Tables S3).

Manual IBEX

The manual IBEX method is compatible with a wide range of imaging substrates and can be easily adapted to diverse systems including upright and inverted microscopes. We have performed IBEX on upright microscopes with tissues adhered to slides. However, we prefer using an inverted microscope with a chambered coverglass as it eliminates the need for coverslip removal between cycles. When preparing chambered coverglass samples, it is important to place the tissue in the center of the well to prevent any damage to microscope objectives. To ensure a uniform focal plane and secure adherence, the tissue must be carefully flattened onto the glass surface with a paintbrush (Extended Data Figure 1a). For 20-30 μm tissue sections, we utilize the PELCO BioWave Pro 36500-230 microwave for antibody labelling; however, comparable immunolabeling is observed for thin ($\sim 5\text{-}10\ \mu\text{m}$) tissue sections incubated for 1 hour at 37°C. Before fluorophore inactivation with LiBH_4 , we extensively wash the sample (3 exchanges of 1 ml of PBS) to remove mounting media. We additionally wait until small bubbles form in the LiBH_4 solution, typically 10 minutes after dissolving in water, before adding to the samples. Small bubbles routinely form on the tissue during the 15-minute incubation of LiBH_4 (Extended Data Figure 1b). Because the manual IBEX method involves removing the sample from the microscope stage for iterative rounds of fluorophore inactivation and immunolabeling, careful attention must be paid to the alignment of images acquired over distinct cycles. We achieve this by matching shared landmarks, such as distinct nuclear morphology, in the first z-slice (Begin) and last z-slice (End) across the different image volumes (Extended Data Figure 1c). Manual execution is required in instances where a fluidics device is not available or compatible with existing instrumentation. Indeed, the IBEX method was initially developed using an advanced confocal instrument equipped with a 405 nm laser and a white light laser source producing a continuous spectral output between 470 and 670 nm. This system confers several advantages over conventional widefield microscopes including the ability to image more markers per cycle and the acquisition of fully resolved 3D z-stacks. However, this instrument is presently incompatible with the automated workflow described below. In addition to overcoming instrument limitations, the manual method provides users a means to acquire highly multiplexed images under experimental conditions not amenable to IBEX automation, e.g. access to pre-cut FFPE slides only.

Automated IBEX

To enable widespread adoption and higher throughput, we designed an automated workflow that could be easily implemented by most laboratories and possessed an economical equipment footprint (Figure 2a-c, Extended Data Figure 2). We achieved this goal by integrating an inverted widefield microscope (Leica Microsystems THUNDER imaging system) and a compact fluidics device (Fluigent ARIA). Our selection of an imager was based on the following technical specifications: i) ability to image multiple fluorophores per cycle, ii) stable multi-hour (>16 hours) acquisitions with pixel-pixel alignment across imaging cycles, iii) external triggering capabilities to interface with fluidics device, and iv) capture of multiple regions of interest with tiling in 2D and 3D. Of note, the THUNDER computational clearing and adaptive deconvolution software provides confocal quality images (based on contrast) in a fraction of the time and cost of traditional laser scanning confocal microscopes, making it particularly attractive for IBEX automation. With regards to the fluidics device, we required an instrument that was able to send and receive Transistor-Transistor Logic (TTL) pulses while supporting delivery of multiple solutions. The Fluigent ARIA possesses 10 reservoirs and typical experiments utilize the following configuration: i) LiBH_4 in Reservoir 1, ii) Hoechst labelling in Reservoir 2, iii) Antibody panels in Reservoirs 3-8, and iv) PBS wash in Reservoir 10 with an empty Reservoir 9. However, it is possible to deliver 7 unique antibody solutions with 4 fluorophores per cycle to achieve a 29-parameter dataset (7 cycles of 4 fluorophores

per cycle plus Hoechst as a fiducial) in one execution of the program. Samples are prepared using coated 22 mm square coverslips and the RC-21B closed bath imaging chamber supplied by Warner Instruments (Figure 2b, Extended Data Figure 2). In addition to supporting linear solution flow, the closed bath system provides a large viewing area with a total bath volume of 358 μl , greatly reducing antibody labelling costs. Together, the protocol steps of immunolabeling, imaging, and fluorophore inactivation (Figure 2c) can be automated using commercially available instruments and reagents to obtain highly multiplexed images.

SimpleITK image registration

Both versions of IBEX yield a series of images that are collected separately as either 3D image stacks (manual) or 2D single z-slices (automated). Using SimpleITK, we developed an intensity-based image alignment protocol to register 2D and 3D IBEX-generated images. In our initial report, we improved upon existing algorithms^{50,51} by providing a workflow capable of aligning large datasets (>260 GB) that additionally offers flexibility with regard to the fiducial used for registration²³. To assess the quality of image alignment, a cross correlation matrix may be generated using a marker channel that is repeated across the cycles. Here, we document a user-friendly solution for image alignment by developing an executable that is compatible with Imaris, a commercial microscopy analysis software suite in worldwide use. Through the freeware Imaris Viewer and SimpleITK Imaris XTension, biologists without programming experience can obtain cell-cell registration across x-y-z dimensions from iterative cycles of IBEX at limited cost.

Advantages and limitations

IBEX has several advantages over existing multiplexed antibody-based imaging methods including its i) open and flexible nature, ii) capacity to utilize different imaging platforms, iii) short immunolabeling and bleaching time, iv) unrestricted compatibility with hundreds of commercial antibodies conjugated to diverse fluorophores, and v) simple implementation by biologists in standard laboratory environments. To date, we have demonstrated that 12 fluorophores, corresponding to 8 distinct imaging channels, can be inactivated within 10-20 minutes of LiBH_4 treatment alone. In contrast, methods employing H_2O_2 for fluorophore inactivation are limited to 7 fluorophores, representing 3 imaging channels, and require 1 hour in the presence of light for signal elimination⁸. Thus, the ability to inactivate diverse fluorophores in a short period of time is a significant advantage over existing iterative imaging methods. Importantly, treatment of fixed frozen tissue sections with LiBH_4 does not result in tissue loss as we previously found for H_2O_2 ²³. The work outlined here and previously²³ offer a resource to the field of antibody-based imaging by providing exhaustive lists of validated reagents and approved panels for mouse and human tissues. It is our intent to enable high quality data generation while defraying the substantial cost, many thousands of US dollars for a 50-plex panel, and time, around 6 months, to develop equivalent panels *de novo*¹⁹. The primary limitation of the original IBEX method was that it required manual execution; however, we now have an affordable automated solution for high content imaging (Table S4). Presently, the thickness of tissue that can be imaged is restricted to <50 μm due to local tissue warping and distortion across iterative cycles. Beyond increasing the tissue volume that can be acquired (>400 μm), future improvements include custom fabrication of imaging chambers >22 mm^2 to enable automated acquisition of larger tissue areas including whole slide scans and tissue microarrays. We are actively working on methods that increase the number of parameters that can be imaged in a single IBEX cycle by employing additional IBEX compatible fluorophores and confocal microscopes equipped with advanced detectors and extended spectral outputs of 440-790 nm. While high numerical aperture (NA) objectives (40x, 1.3) have been shown to work well in IBEX imaging, we have not yet carefully tested higher magnification (63x, 100x) or higher NA (1.4) objectives for resolving subcellular structures.

Materials

- *Ethics and biological materials*
 - Human Tissue
 - Human tissue was obtained on a NIH Institutional Review Board (IRB)-approved protocol (13-C-0076) at the time of risk-reducing surgery performed as a consequence of germline genetic mutation(s). All tissue procured, which included biopsies of lymph nodes, skin, spleen, liver and jejunum, was grossly normal as determined by the operative surgeon and histopathologically normal as determined by a board-certified pathologist. Of note, all tissue was obtained within twenty minutes of skin incision given our observation of neutrophil infiltrate with prolonged (>1 hour) procedures. Human kidney samples were collected from patients undergoing elective renal surgery at Hannover Medical School. Samples were enrolled in this study after histologic assessment only after completion of routine diagnostics and written consent approved by the local ethics committee of Hannover Medical School (ethics-vote number: 3381-16, 2893-15, 1741-13).
 - **Caution:** Any experiments involving human tissues must conform to relevant institutional and national regulations. All procedures described in this protocol were approved by an IRB.

Reagents and consumables

- *Tissue grossing and processing*
 - BD Cytotfix/Cytoperm (BD Biosciences, cat no. 554722)
 - Camel hair brush (Ted Pella, Inc., cat no. 11859)
 - Cell culture plate 6 well (Corning, cat no. 3335)
 - Cell Pro 500 ml 0.22 μ m Bottle Top Filter (Alkali Scientific, cat no. VH50022)
 - Histomolds, 10mm x 10mm x 5mm (Sakura, cat no. 4565)
 - Histomolds, 15mm x 15mm x 5mm (Sakura, cat no. 4566)
 - Low profile microtome blades (Leica Biosystems, cat no. 14035843496)
 - Optimal cutting temperature (OCT) compound (Sakura, cat no. 4583)
 - Regular bevel needles 30G (BD, cat no. 305106)
 - Sucrose Solution
 - Prepare by dissolving 30% (wt/vol) Sucrose (Millipore Sigma, cat no. S0389) in sterile 1X PBS and pass through a 0.22 μ m bottle top filter. The solution can be stored at 4°C for several months if kept sterile.
 - UltraPure agarose (ThermoFisher Scientific, cat no. 16500-500)
- *Manual and automated IBEX: Tissue blocking, antibody immunolabeling, and fluorophore inactivation*
 - Antibodies (See Tables S1-S2)
 - Blocking Buffer
 - Solution made from 1X PBS (Gibco, cat no. 10010-023) containing 0.3% Triton-X-100 (Millipore Sigma, cat no. 93443), 1% Bovine Serum Albumin (Millipore Sigma, cat no. A1933) and 1:100 dilution of Human (BD, cat no. 564219) or Mouse (BD, cat no. 553141) Fc-block
 - diH₂O (Quality Biological, cat no. 351-029-101)
 - Fluoromount-G (Southern Biotech, cat no. 0100-01)
 - Hoechst 33342 (ThermoFisher Scientific, cat no. H3570)
 - Lithium borohydride (STREM Chemicals, cat no. 93-0397)
 - 20 ml Disposable syringe with luer-lock tip (EXEL Int., cat no. 26280)

- Millex-GS Syringe Filter Unit (0.22 μm) (Millipore Sigma, cat no. SLGSM33SS)
- Manual IBEX
 - *Sample preparation (Fixed frozen)*
 - Chrome Alum Gelatin (Newcomer Supply, cat no. 1033A)
 - 2-well chambered coverglass (Lab-Tek, cat no. 155380)
- Automated IBEX
 - *Sample preparation (Fixed frozen)*
 - Chrome Alum Gelatin (Newcomer Supply, cat no. 1033A)
 - Cover glass 22x22 mm #1.5 (Electron Microscopy Sciences, cat no. 63786-10)
 - *Sample preparation (FFPE)*
 - AR6 buffer 10X (Akoya Biosciences, cat no. AR600250ML)
 - Chrome Alum Gelatin (Newcomer Supply, cat no. 1033A)
 - Cover glass 22x22 mm #1.5 (Electron Microscopy Sciences, cat no. 63786-10)
 - Ethanol, 200 Proof (Decon Labs, Inc., cat no. 2701)
 - Formalin, 10% neutral buffered (Cancer Diagnostics, Inc., cat no. FX1003)
 - TBST wash buffer
 - Solution made from 1X TBS (Quality Biological, cat no. 351-086-101) and 0.05% Tween 20 in diH₂O (Millipore Sigma, cat no. 9005-64-5)
 - Xylene, histology grade (Newcomer Supply, cat no. 1446C)
 - *Chamber assembly*
 - Dow Corning® high-vacuum silicone grease (Millipore Sigma, cat no. Z273554)
 - 10 ml size Luer-lock syringe (BD, cat no. 309604)

Equipment and tools

- *Tissue grossing, processing, and sample preparation*
 - Cryostat (Leica Biosystems, CM1950) or a comparable instrument
 - Dissecting mat, flexible, polypropylene (Newcomer Supply, cat no. 5218A)
 - Dissecting needles (Newcomer Supply, cat no. 5220PL)
 - Fine forceps (Fine Science Tools, cat no. 11412-11)
 - Forceps, custom embedding 13 cm, curved, standard grade (Newcomer Supply, cat no. 5536)
 - Scissors (Fine Science Tools, cat no. 114090-09)
 - Small digital incubator (Boekel Scientific, 133000)
 - Sterile disposable scalpels #11 (Newcomer Supply, cat no. 6802A)
 - Stereomicroscope (Zeiss, Stemi 2000-CS) or a comparable instrument
 - Stereomicroscope illuminator (Zeiss, KL 1500 LCD) or a comparable instrument
- *Automated IBEX: Sample preparation (FFPE)*
 - EasyDip slide staining kit (Newcomer Supply, cat no. 5300KIT)
 - EasyDip anodized aluminum jar rack holder (Newcomer Supply, cat no. 5300JRK)
 - Glass beaker, 100 ml (VWR, cat no. 10754-948)
 - Rotary microtome (Leica Biosystems, RM2255) or a comparable instrument
 - StatMark pen (Electron Microscopy Sciences, cat no. 72109-12)
 - Wash N'Dry cover slip rack (Electron Microscopy Sciences, cat no. 70366-16)

- *Manual IBEX: Immunolabeling and microscopy*
 - Confocal microscope
 - The default for this protocol uses an inverted Leica TCS SP8 X confocal microscope equipped with a 40x/1.3 objective, 4 HyD and 1 PMT detectors, a white light laser source that produces a continuous spectral output between 470 and 670 nm as well as an additional 405 nm laser. Images were captured at 8-bit depth, with a line average of 3, and 1024x1024 format with the following pixel dimensions: x (0.284 μ m), y (0.284 μ m), and z (1 μ m). Images were tiled and merged using the LAS X Navigator software (LAS X 3.5.5.19976). Other confocal microscopes with comparable specifications in terms of laser lines, objectives, detectors, precision stage, and control software can be used. We prefer inverted over upright microscopes because these systems eliminate the need for coverslip removal, a tedious step that can lead to tissue loss.
 - PELCO BioWave Pro microwave (Ted Pella Inc., 36500-230) equipped with a PELCO SteadyTemp Pro (Ted Pella Inc., 50062) thermoelectric recirculating chiller
 - This specialized, non-heating microwave accelerates immunolabeling without tissue loss or epitope damage.
 - Slide moisture chamber (Scientific Device Laboratory, cat no. 197-BL)
- *Automated IBEX: Immunolabeling and microscopy*
 - 31G insulin syringes (BD, cat no. 328438)
 - ARIA fluidics system
 - ARIA automated perfusion system (Fluigent, cat no. CB-SY-AR-01)
 - Fluigent Low Pressure Generator (FLPG) pressure supply (Fluigent, cat no. FLPG005)
 - BNC Male to SMB Plug Cable RG-316 Coax in 120-inch length (2 needed in total) for TTL triggering (Fairview Microwave, cat no. FMC0816315-120)
 - Imaging chamber, vacuum, and heater
 - CC-28 Cable assembly for heater controllers to platform (Warner Instruments, cat no. 64-0106)
 - Dedicated Workstation Vacuum System (Warner Instruments, cat no. 64-1940)
 - PM-2 Platform for Series 20 chambers, magnetic clamps, heated (Warner Instruments, cat no. 64-1561)
 - Before first use, the electrode prongs need to be carefully bent upwards 30 degrees to allow the assembled unit to fit into the stage adapter. This can be done with a pair of forceps.
 - RC-21B Large Closed Bath Imaging Chamber (Warner Instruments, cat no. 64-0224)
 - SA-20PL Series 20 stage adapter (Warner Instruments, cat no. 64-0299)
 - TC-324C Single Channel Temperature Controller (Warner Instruments, cat no. 64-2400)
 - Leica THUNDER microscope
 - The system employed in this automated IBEX protocol is a THUNDER 3D Cell Culture microscope with a high precision (Quantum) stage, a high quantum efficiency sCMOS camera (DFC9000 GTC) and a 40x/1.3 NA oil objective. The system includes an adaptive focus control unit, to ensure image focus over many hours of imaging and fluidic cycle times. The LED8 light source has 8 individual LED lines for excitation with millisecond triggering. Two advanced sequencer boards were installed in the control box of the microscope configured to use SMB connections to send and receive external triggers from additional

- devices. A spill guard was installed on the objective turret to ensure no liquids enter the microscope body.
- For fluorescence imaging, a custom quad-band filter with external filter wheel (PN: 11536075) with two additional single-band filters (PN: 8118215) were used to image 7 dye channels per pass. The filter excitation, dichroic and emission lines are listed below.
 - Quad-Band cube: dichroic at 391/32, 479/33, 554/24, 638/31, no excitation or emission filters.
 - External filter wheel position 1: 434/32, position 2: 520/40, position 3: 585/20, position 4: 720/60, position 5: pass-through.
 - Single-band 1 - 585/22 excitation, 594 dichroic, 625/30 emission.
 - Single-band 2 - 635/20 excitation, 647 dichroic, 667/30 emission.
 - LAS X [3.7.1.21655], the software used on the THUNDER imager, comes with the primary modules needed to perform the imaging shown here, including the THUNDER computational clearing and adaptive deconvolution routines that utilize Leica Microsystems proprietary algorithms to enhance image contrast and resolution. The additional 'Trigger to Peripherals' (PN: 11640613) module is required and the 'Dye Finder' (PN: 11640863) module is recommended to negate spectral cross-talk. All images were captured at a 16-bit depth with the following pixel dimensions: x (0.160 μm), y (0.160 μm), and z (1 μm).
 - Other inverted widefield microscopes with comparable specifications in terms of light source and filter cubes for excitation and emission of multiple fluorophores, precision stage, adaptive focus control or other means of maintaining the same focus position over multiple cycles, objective choice, camera sensitivity and resolution, control software, deconvolution algorithms, and the ability to send and receive external triggers can be used.
- *Software*
 - Imaris and Imaris File Converter (x64, version 9.5.0 and higher, Bitplane)
 - Python (version 3.7.0 and higher)
 - Custom Imaris Extension (XTRegisterSameChannel, open source software distributed under Apache 2.0 license)
 - *Equipment Setup*
 - Automated IBEX connection of ARIA fluidics device to LAS X software
 - Prior to using the ARIA with LAS X, the triggers must be programmed into your hardware configuration and the cabling attached. Here we name them 'ARIA to Leica' and 'Leica to ARIA'.
 - Before imaging, set up the triggers in the hardware configuration. Within LAS X hardware configurator, navigate to the sequencer tab under 'Configure'. Add two new triggers from the available triggers, if you do not have an open trigger on the sequencer you will need to a) add a sequencer or b) remove a triggered device.
 - For the first trigger, give it a name (i.e. 'Leica to ARIA'), select 'output' and list it as a TTL output. The second trigger will also be named (i.e. 'ARIA to Leica') and listed as a TTL but will be set as 'input'.
 - Once programmed, connect a SMB to BNC cable from the sequencer output for the 'output' trigger to the 'IN' connection on the ARIA.
 - Connect a second SMB to BNC cable from the sequencer 'input' trigger to the 'OUT' connection of the ARIA.
 - Software Installation for SimpleITK Imaris Python Extension

- For initial setup, install Python 3.7.0 and download our Imaris extensions code repository as a zip file: (https://github.com/niaid/imaris_extensions/archive/refs/heads/main.zip). Installation instructions are available online: [https://github.com/niaid/imaris_extensions] and in the README.md file which is part of the zip file.
- Additional details can be found in the XTRegisterSameChannel SimpleITK Imaris Python Extension YouTube tutorial (<https://youtu.be/rrCajl8jroE>). To illustrate the usage of this software we provide sample data on Zenodo [<https://doi.org/10.5281/zenodo.4632320>].

Procedure

Manual and Automated IBEX

Tissue grossing

Timing: 2-3 hours, depending on the number and type of samples

- 1) Survey the organ specimens for distinct anatomical landmarks that may aid in tissue orientation, and, whenever possible, preserve these metadata. If biopsies are assessed, clinical imaging data (Computerized Tomography (CT) scan, ultrasound) of the biopsy procedure is helpful.
- 2) Prepare samples with dissecting tools (scalpel, forceps, scissors) on a dissecting mat or other clean, fiber-free surface. For small samples, a stereomicroscope and illuminator may be required for careful dissection (Figure 1). See Box 1 for tissue specific details.

Critical: Work quickly to minimize tissue damage from autolysis.

Caution: Be careful around cutting implements and properly dispose of sharps. Use proper personal protective equipment (PPE) to reduce exposure to potential blood- or air-borne pathogens.

Tissue processing

Timing: 2 days

- 3) Our preferred method of fixation uses 1 ml of BD Cytofix/Cytoperm for every 3 ml of 1X pH 7.4 PBS. Please consult published methods for preparing FFPE samples³⁸. Transfer thin (a few mm) tissue sections (skin, lymph node, wedge resections) to a 50 ml conical tube with 20 ml of fixative. For the bowel, completely submerge the pinned tissue in fixative. The ideal ratio of fixative to tissue is 20:1. Incubate at 4°C for 16-24 hours.

Critical: Be mindful of the expiration date published on the BD Cytofix/Cytoperm bottle. If working with potentially infectious samples, identify the fixation conditions that fully inactivate pathogen(s) before preserving samples as described above. For example, an internal biosafety review committee found that increasing the incubation period to 72 hours inactivated SARS-CoV-2 virus particles in mouse lung tissues. Importantly, tissue epitopes were well preserved under these conditions.

Caution: Formaldehyde is a known carcinogen and environmental hazard. Wear PPE and dispose of waste properly.

- 4) Wash samples twice, less than 5 minutes per wash, in 1X PBS at room temperature to remove excess fixative.
- 5) Place sample in 30% sucrose (wt/vol) and incubate at 4°C for 16-24 hours.
- 6) Fill a Histomold with OCT medium and embed the tissue. The tissue should occupy less than 60% of the mold volume. Freeze by placing the Histomold on dry ice. Using forceps, ensure the tissue is correctly oriented in the Histomold for subsequent sectioning. For orientation guidance see Box 1.
- 7) Wrap in foil and store at -80°C.

Pause Point: Cryopreserved tissues can be left at -80°C for several years.

Manual IBEX

Sample preparation

Timing: 2.5 hours

- 8) Remove the tissue block from -80°C and allow it to equilibrate to the chamber temperature of the cryostat for 1 hour.
- 9) While blocks are equilibrating in the cryostat (1 hour), coat a 2-well chambered coverglass by pipetting 15 µl of chrome alum gelatin into each glass well. Use a pipette tip or smaller coverslip (18x18 mm) to spread the solution. Dry for 1 hour in a 60°C oven.
Critical: It may require multiple passes to get an even film on the coverglass. Aspirate any large accumulations as these can form autofluorescent regions. Do not use the adhesive past the stated expiration date as tissue adherence will be compromised.
- 10) Prepare 20-30 µm sections with a cryostat. Section tissue directly onto the 2-well chambered coverglass.
Critical: The tissue section should be completely flat and centered within the well. It is worth preparing several backup samples during each session.
Caution: Be careful around cutting implements and properly dispose of sharps. Use PPE to reduce exposure to blood- or air-borne pathogens.
- 11) Dry sections onto coated 2-well chambered coverglass for 1 hour at 37°C or overnight at room temperature.
Critical: Do not store chambered coverglass with sectioned tissue in a -20°C freezer or the tissue will lift. It is best to use the chambers within 1-2 days of preparation.

Tissue blocking and antibody immunolabeling

Timing: 1 hour

- 12) For a 2-well chambered coverglass, add 1 ml of 1X PBS to each well to rehydrate the tissue. Incubate for 5 minutes at room temperature.
- 13) Add 400 µl of Blocking Buffer per well. Place humidity chamber with 2-well chambered coverglass into the BioWave Pro microwave directly on the cooling plate. Switch on the SteadyTemp Pro 50062 Thermoelectric Recirculating Chiller set to 26°C.
Critical: Ensure the cooling plate is filled with ultrapure water, no air or bubbles are present, and the temperature probe is secured. Make sure that the SteadyTemp cooler option is activated in the software.
- 14) Start one cycle of the microwave program. A 2-1-2-1-2-1-2-1-2 program is used where '2' denotes 2 minutes at 100 watts and '1' denotes 1 minute at 0 watts. The above program is executed once for blocking and secondary antibody labelling and twice for primary antibody labelling. Alternatively, thin tissue sections (5-10 µm) can be immunolabeled for 1 hour at 37°C.
- 15) Aspirate the Blocking Buffer.
- 16) Add 400 µl of primary antibody solution per well. Perform two cycles of the microwave program or incubate for 1 hour at 37°C (5-10 µm sections).
Critical: It is important to carefully validate and titrate all antibodies for optimal immunolabeling prior to implementation in IBEX protocols, preferably with sections of the same tissue.
- 17) Aspirate the antibody solution and wash with 3 exchanges of 3 ml of 1X PBS. The entire wash step can be performed in 5 minutes.
- 18) If a secondary antibody is to be used add this now in 400 µl of Blocking Buffer and perform one cycle in the microwave as above or incubate for 1 hour at 37°C (5-10 µm sections). Then wash with 3 exchanges of 3 ml of 1X PBS.
Critical: Do not include secondary antibodies that will cross-react with primary antibodies in multiplexed panels. Always use highly cross-adsorbed secondary antibodies to prevent off-target immunolabeling.
- 19) Add 1 ml of Fluoromount-G to samples.
Critical: It is beneficial to leave samples for 30 minutes at room temperature in the dark to allow the tissue to equilibrate and settle before imaging.

Pause Point: Samples are stable in mounting media for several days at room temperature in the dark; however, we obtain the best results when images are acquired within 24 hours of immunolabeling.

Microscope setup and imaging

Timing: 4 hours

- 20) Clean the bottom of the chambered coverglass with lens cleaner and lens paper immediately before imaging. Add immersion oil to the glass surface and place on the microscope stage.
- 21) Slide the chamber firmly into the top left corner (or equivalent) of the stage insert, so the tissue will be consistently positioned in the XY plane.
- 22) Image on a confocal inverted microscope. We use a Leica TCS SP8 X system as outlined here.
- 23) Using Leica LAS X Navigator software, define the tissue volume to be acquired (number of tiles and z-stack size). Be sure to note the tile number and z-stack volume as this will be kept constant throughout all cycles.
- 24) To minimize spectral overlap, perform multiple scans using separate detectors with sequential laser excitation of compatible fluorophores.
- 25) Following image acquisition, correct for spectral overlap between fluorophores (Box 2).

Fluorophore bleaching

Timing: 30 minutes

- 26) Clean off immersion oil and thoroughly aspirate Fluoromount-G with a pipette.
- 27) Perform three exchanges of 3 mL of 1x PBS to completely dissolve and wash away the Fluoromount-G.

Critical: It is imperative that all Fluoromount-G be removed for bleaching to be effective.

- 28) Prepare a 1 mg/mL solution of LiBH_4 in dH_2O .

Caution: Perform these steps in a chemical hood with appropriate PPE. The reaction can generate hydrogen gas, which is flammable. To avoid flames, always work with small amounts (<10 mg) of LiBH_4 . Store LiBH_4 in a sealed container with desiccant and use a new vial of LiBH_4 no later than 4 weeks after opening original container.

Critical: Leave the solution to incubate at room temperature for 10 minutes after gentle mixing. Formation of bubbles indicates the solution is ready. The solution must be used within 4 hours or it becomes ineffective. The solution can contain manufacturing impurities and should be passed through a 0.22 μm syringe filter.

- 29) Add the LiBH_4 solution to the tissue. The tissue should be completely covered by the solution. For a chambered coverglass, we add 1 ml per well. Incubate for 10 minutes at room temperature exposed to standard ambient lighting.
- 30) **Optional:** If using BV421 and BV510 dyes, add LiBH_4 to the chamber and place on the microscope stage. Turn the epifluorescence lamp to maximum power, select the DAPI filter, focus on the tissue, and scan across the acquired region of interest using the eye piece to observe signal loss (1-2 minutes per field of view).
- 31) Perform three exchanges of 3 mL of 1X PBS to completely wash away the LiBH_4 solution.

Critical: Incomplete washing can lead to bleaching of the subsequent panel of antibodies.

Cycles of tissue labeling, image acquisition, and fluorophore bleaching

Timing: 6 hours

- 32) Add the next panel of antibodies and repeat the procedure from Steps 16 to 19.
- 33) Extra attention is required when placing the sample back onto the microscope stage. The XY plane should be similar due to consistent positioning in the stage insert.
- 34) Open the image acquired from Cycle 1 in the LAS X Navigator software by right-clicking the desired image and selecting "Open in New Viewer". Scroll to the top of the z-stack (Begin) and click "Live" to view the sample presently on the microscope stage (Cycle 2, for example).

- 35) Using the channel that contains the repeated marker (Hoechst), identify unique structures (nuclear shapes) that are present in the “live” image (Cycle 2, for example) and the previous image (Cycle 1). Set this z-position as your Begin. To set the End, repeat this step while preserving the total z-stack volume captured in the previous image (8 μm).
- 36) Image using the same parameters established for the image acquired during Cycle 1.
Critical: It may be necessary to check alignment across different XY regions of the tissue. Distinctive tissue structures such as nuclei are useful to achieve fine alignment (Extended Data Figure 1c).
- 37) Repeat Steps 26-31 to inactivate LiBH_4 -sensitive fluorophores.
- 38) Repeat Steps 32-36 to reach the desired number of cycles and markers. Process images using Steps 78-90.

Automated IBEX

Sample preparation

Timing: 2 hours for fixed frozen tissues (40A); 3.5 hours for FFPE tissues (40B)

- 39) Coat a square 22x22 mm #1.5 glass coverslip by adding 3 μl of chrome alum gelatin to one side. Spread evenly using the edge of another coverslip and dry for 30-60 minutes in a 60°C oven. Denote the coated side of the coverslip using a symbol with a StatMark pen. We always mark the lower right corner with a series of characters that can only be read in one direction (QJZ). This prevents confusion if the coverslip is reoriented over the course of the experiment (sectioning, chamber assembly).
- 40) For fixed frozen tissue follow Option (A), for FFPE tissue follow Option (B):
 - A. Fixed frozen tissue preparations
 - I. Using a cryostat, section the OCT embedded tissue at 10 μm thickness onto the center of the coverslip and dry overnight at room temperature or for 1 hour at 37°C.
Critical: Ensure the tissue section is completely flat and centered on the glass coverslip. It is worth preparing several backup samples during one session.
Caution: Be careful around cutting implements and properly dispose of sharps. Use PPE to reduce exposure to blood- or air-borne pathogens.
Pause Point: The dried samples can be stored (covered) at room temperature for up to 5 days before use; however, we recommend acquiring images within 1-2 days of sample preparation.
 - B. FFPE tissue preparation
 - I. Use a microtome to cut sections at 5 μm .
Caution: Be careful around cutting implements and properly dispose of sharps. Use PPE to reduce exposure to blood- or air-borne pathogens.
 - II. Float tissue onto coated coverslips using the same technique utilized for FFPE sections on glass slides.
 - III. Place in a 60°C oven for 1 hour to adhere the tissues to the coverslips.
 - IV. To deparaffinize the tissue, place coverslips in a Wash N'Dry coverslip rack. Add 100 ml of the solutions listed in (V-X) to individual jars (8 in total) of the EasyDip slide staining kit and rack. Use forceps to transfer the coverslip rack between jars. Do not allow the tissue to dry out at any stage.
 - V. 100% Xylene for 10 minutes.
 - VI. 100% Xylene for 10 minutes.
 - VII. 100% Ethanol 10 minutes.
 - VIII. 95% Ethanol for 10 minutes.
 - IX. 70% Ethanol for 5 minutes with quick wash (< 1 minute) in water.
 - X. 10% Formalin for 15 minutes with quick wash (< 1 minute) in water. TBST for 5 minutes.
 - XI. For antigen retrieval, place coverslips (in Wash N'Dry coverslip rack) in a glass beaker with 100 ml of a 1X solution of AR6 buffer.

- XII. Place beaker in a 95°C water bath and incubate for 40 minutes. Remove from the water bath and allow to gradually cool on the bench for at least 20 minutes.
- XIII. Replace 1X AR6 buffer with 1X PBS and cover glass beaker with aluminum foil.

Pause Point: The samples can be stored in PBS at room temperature for up to 2 days before use.

Critical: Always check the antigen retrieval conditions specified by the antibody vendor before immunolabeling as the buffer(s) suitable for one epitope may be incompatible with another epitope. For this reason, we optimize the antigen retrieval protocol to obtain conditions that work for all antibodies used in our experiments.

Caution: Perform deparaffinization in a properly functioning chemical hood. Read the safety data sheets associated with these chemicals and take proper precautions before handling. Xylene and formalin (formaldehyde) are known physical and environmental hazards. Additionally, xylene and ethanol are highly flammable liquids.

Chamber assembly

Timing: 15 minutes

- 41) Fill a 10 ml Luer-lock syringe with vacuum grease, by initially removing and then replacing the plunger.
Critical: Ensure the vacuum grease is fresh and white in color. Yellow discoloration is a sign of degradation and can lead to chamber leakage.
- 42) Coat the base of the RC-21B chamber first, by piping a line of vacuum grease 2 mm in diameter along the four sides of the square recession. Spread the grease evenly using a pipet tip.
Critical: Avoid getting vacuum grease in the RC-21B fluid inlet or outlet ports to prevent fluid obstruction.
- 43) Apply the coverslip with adhered tissue to the base, ensuring the side with the tissue faces upwards into the chamber. Gently press around the perimeter of the coverslip to ensure a continuous interface of grease surrounds, but does not spill, into the central chamber.
Critical: If using FFPE tissue, keep the tissue wet by adding a drop of PBS onto the tissue while preparing the chamber.
- 44) Repeat Steps 42 and 43 with the following alterations: coat the top (not the base) of the RC-21B chamber with vacuum grease and use a fresh 22x22 mm coverslip (no tissue) to create a closed bath chamber.
- 45) Place the RC-21B chamber into the PM-2 magnetic platform with outflow side adjacent to the Warner label. Apply the magnetic clamp, keeping the Warner label on the platform base proximal to the Warner label on the magnetic clamp. See Extended Data Figure 2.

Prepare required solutions

Timing: 45 minutes

- 46) PBS can be added directly from a 1X stock to the provided glass container in Reservoir 10 of the ARIA.
- 47) Hoechst and Blocking Solution: Add 1 µl of Hoechst 33342 and 10 µl Fc-block to 1 ml of Blocking Buffer described in Reagents section.
- 48) Antibody Panels: In 400 µl total volume of Blocking Buffer, prepare antibody panels for each iterative cycle using previously determined titrations.
Critical: Do not include secondary antibodies that will cross-react with primary antibodies in multiplexed panels. Always use highly cross-adsorbed secondary antibodies to prevent off-target immunolabeling.
- 49) LiBH₄: Prepare at least 5 ml of a 0.5 mg/ml LiBH₄ solution (dissolved in diH₂O).
Caution: Perform these steps in a chemical hood with appropriate PPE. The reaction can generate hydrogen gas which is flammable. To avoid flames, always work with small amounts (<10 mg) of LiBH₄. Store LiBH₄ with desiccant and use a new vial of LiBH₄ no more than 4 weeks after opening the primary container.

Critical: Only make this solution just before the run starts. The solution becomes less effective at bleaching and will need replacement after 4 hours. The solution can contain manufacturing impurities and must be passed through a 0.22 μm syringe filter before adding to the ARIA fluidics device.

Prepare the ARIA unit

Timing: 10 minutes

50) Switch on the FPLG unit and ensure a minimum of 2.2 bar is reached before switching on the ARIA unit power supply and starting the Fluigent Controller Software on the attached computer.

Critical: If not already done, perform a calibration run and record the values, making sure these recorded values appear whenever the software is restarted.

51) Create a custom ARIA program based on the example steps outlined below. Load this sequence before each run.

52) Add solutions to the reservoirs specified in the program on the ARIA machine. Our standard configuration is: LiBH_4 (Reservoir 1), Hoechst + Fc block (Reservoir 2), Antibody Panels (Reservoir 3-8), and PBS (Reservoir 10).

Critical: Only 15 ml Falcon™ brand tubes fit the taper to ensure an airtight seal.

Example ARIA Sequence Program for a 6 cycle experiment (Total time: ~630 minutes (10.5 hours))

Step	Step action	Flow rate ($\mu\text{l}/\text{min}$)	Total volume (μl)	Time (Minutes)	TTL	Purpose
0	Prefill			3		Load the fluid lines with PBS
1	Flush tubing	200	Variable	0.5		Fill lines with PBS up to the 2-switch
2	Volume injection of PBS	120	800	~7		Rehydrate tissue
3	Volume injection of Hoechst	120	300	2.5		Nuclear labeling (Hoechst)
4	Wait			5		Nuclear labeling with Hoechst
5	Volume injection of PBS	120	600	5		PBS wash
6	Wait for user			5-10		User defines ROI and z-slice
7	Volume injection of Antibody #1	120	300	2.5		Injection of Antibody
8	Wait			60		Antibody immunolabeling
9	Volume injection of PBS	120	1200	10	ARIA to THUNDER	PBS wash and signal to THUNDER for imaging
10	Wait for TTL			~10	THUNDER to ARIA	Wait for imaging to complete and signal to ARIA
11	Volume injection of PBS	120	240	2		Fluid spacer between antibodies and LiBH_4
12	Volume injection of LiBH_4	120	1200	10		Fluorophore inactivation with LiBH_4
13	Volume injection of PBS	120	1200	10		PBS wash
14	Repeat steps 7-13 for 4 times					
44	Volume Injection	120	300	2.5		Injection of Antibody #6
45	Wait			60		Antibody immunolabeling
46	Volume injection of PBS	120	1200	10	ARIA to THUNDER	PBS wash and signal to THUNDER for imaging
47	Wait for TTL			~10	THUNDER to ARIA	Wait for imaging to complete and signal to ARIA

48	Wait for user			Variable		Instrument paused until user input received
----	---------------	--	--	----------	--	---

Initial setup of the THUNDER microscope

Timing: 5 minutes

53) Switch on microscope and LED8 source. Launch LAS X software. Select objective (this protocol is optimized for a 40x/1.30 oil immersion objective). Place the camera into 16-bit mode in the configuration tab. Select the required channels based on the fluorophores present in antibody panels. Set LED power to 25% with 150 ms exposure time for all.

Critical: If using an AF750 filter combination, increase LED power to 40% for this channel as the signal is greatly reduced with the AFC function.

54) Highlight the Hoechst channel and turn on the Linked Shading feature. Follow the command prompts using the Leica THUNDER dialog box to set this for each objective on first use.

55) The LAS X Dye Separation module may be used to compensate for spectral spillover between channels. See Box 2 for details.

Prepare microscope stage

Timing: 5 minutes

56) Insert the Warner SA-20PL stage holder into the motorized microscope stage base.

57) Clean the bottom coverslip of the PM-2 thoroughly with lens cleaner to remove any vacuum grease or marks. If using the recommended 40x/1.30 oil objective, coat the bottom surface of the coverslip generously with immersion oil across a wide region and avoid bubbles.

58) Insert and fasten the assembled imaging chamber and PM-2 magnetic platform into the stage holder. Position the assembled unit so that the Warner name is on the right side and the baseplate temperature probe hole is at the top. See Extended Data Figure 2.

59) Attach the inlet tubing firmly into the RC-21B chamber.

60) Arrange and attach the electrical cables for the heater to the prongs on the PM-2 platform.

61) Insert the temperature probe into the hole at the top of the PM-2 platform.

62) Attach the vacuum line to the reservoir outlet and switch on the vacuum system.

Tissue rehydration and nuclear staining

Timing: 25 minutes

63) Ensure the waste line is connected to an empty container and follow institute recommendations for waste disposal.

64) Prepare the LiBH_4 now and make a 0.5 mg/ml solution in water. Pass the dissolved solution through a 0.22 μm syringe filter. Note the time and use within 4 hours.

65) Switch on the electric heater set to 37°C.

66) Launch the ARIA program.

Critical: Following system priming, the imaging chamber will start to fill. Check there are no leaks. If air is not completely removed from the chamber during filling, loosen the stage insert and gently tilt so air bubbles rise to the outlet channel.

Final setup with triggering of the THUNDER microscope

Timing: 10 minutes

67) Wait for the Fluigent software to reach the programmed pause step. By this point the imaging chamber will be filled, the tissue will be rehydrated, and nuclear staining with Hoechst 33342 will be complete.

68) In the LAS X software, click the “Live” button to visualize the Hoechst staining and bring the center of the tissue into sharp focus.

69) Click on the “Show Highspeed Autofocus Panel” then from the Focus-system dropdown choose “Adaptive Focus Control”. Check “AFC on/off” box so it is active. Choose ‘Continuous mode’ and AFC mode ‘Quality’.

Critical: The green light should appear and hold position remain stable. If this fails, adjust the focus up and down. Intermittent flickering is acceptable.

- 70) Set up THUNDER deconvolution. Recommended parameters are to use the ICC setting with RI set to 1.33. Strength is set to 98% and Feature size is best set to 2000 nm for membrane markers or 3000 nm for nuclear markers in our experience.
- 71) Switch on the 'Timecourse' tab and set the number of cycles to match that of the microfluidics program.
- 72) Enter Navigator mode, map the tissue using the spiral function and create the region of interest for acquisition by tiling.
- 73) While in Navigator select the triggering module.
- 74) With the 'ARIA to Leica' dropdown selected, check "Trigger linked to acquisition" then the check box next to tile number in the Regions Box. In the Channels tab select 'First Channel only', in the Timelapse tab select "Every cycle" and in the Stage tab select "At positions 1"
- 75) Switch to the 'Leica to ARIA' dropdown and check "Use in experiment." Set number of pulses to 1 and to a 100 ms duration. Check the box next to tile number in the Regions box then set the dropdown from Trigger to "After acquisition." In the Channels tab, type the total number of channels being acquired in the "At Channel Number" box. Select "Every Cycle" in the Timelapse tab and ensure the final tile number is shown under the Stage tab under "At positions."
- 76) Click the Start button while in Navigator mode. The software should initialize and move to the first tile position then pause and wait. Now click the popup box to continue the program in the Fluigent software.
 - Critical:** Make sure to check the "hold position" button again in the AFC menu if the z-position is altered at any point.
 - Critical:** Bubbles form on the tissue and rise to the top of the imaging chamber during fluorophore inactivation with LiBH_4 , potentially impeding solution delivery to the tissue. We recommend manually removing air bubbles every 4 cycles. This can be done by placing a 31G tuberculin syringe in the secondary inlet port (See Figure 2b) and aspirating while PBS is injected into the imaging chamber.
 - Critical:** Replace the LiBH_4 after 4 hours of use as its activity diminishes with time. A manual pause can be programmed into the Fluigent software. The ideal workflow is to start the automated IBEX protocol early in the workday. This allows for the replacement of LiBH_4 and bubble removal to be completed before leaving at the end of the day, allowing the system to complete overnight.
- 77) When the cycle is complete the file can be saved and processed with Steps 78-90. Thoroughly clean the RC-21B chamber after each use to remove vacuum grease. Immerse in distilled water to dissolve any precipitated PBS crystals.

Image post-processing

Timing: 45 minutes

- 78) We use commercially available Imaris software (Imaris x64 9.5.0) for processing raw images. Use the Imaris File Converter x64 9.5.0 software to transform the Leica confocal microscope output .lif files into .ims files.
- 79) If using the automated IBEX protocol, iterative images are included as different timepoints of the same image, e.g., timepoint 1 corresponds to cycle 1 image, timepoint 2 corresponds to cycle 2 image, and so on. To obtain individual images (antibody panel 1 from cycle 1, antibody panel 2 from cycle 2) for downstream registration, go to Edit>Crop Time and select from "1" to "1" for timepoint 1 and save using a name with details related to its acquisition, e.g. human_liver_panel1 or human_liver_cycle1. Open the Imaris file with all the timepoints and repeat these steps for each cycle using from "2" to "2" to obtain the timepoint 2 image and so on.
- 80) For each imaging round, edit the file in Imaris and apply any desired processing steps such as image smoothing, channel naming, and channel pseudo-coloring. Channel thresholding and background subtraction can be performed using the Image Processing tools in Imaris to eliminate signal from autofluorescence or left-over signal from incomplete fluorophore inactivation.

- 81) The SimpleITK registration software requires use of a consistent naming strategy. Channels should be uniformly named as prefix-separator character-postfix. Example: "Panel1 CD3_AF594" with space as a separator character for the channel where an anti-CD3 Alexa Fluor 594 antibody was used in the first panel. See help file provided with extension and [https://niaid.github.io/imaris_extensions/XTRRegisterSameChannel.html] for further details.
- 82) Perform image registration using Simple ITK for either manual (3D with z-stack) or automated (2D single z-slice) IBEX.
- 83) Launch the software. Click Imaris Extensions > Simple ITK > Affine Registration of z-stack using common channel.
- 84) One .ims file for each panel of the entire multiplex experiment should be uploaded using the Browse button next to File names. Enter the Channel name prefix separator character. If using the example above, this will be a single space. Click next.
- 85) Select the registration channel. This will be the common named channel used as the fiducial marker, e.g., Hoechst. Select the 'Fixed Image', usually the image file from cycle 1, to which other images will be registered. Select the desired directory under 'Output file'. The 'Start registration at resolution' option is usually set to the maximal resolution to give the best registration possible. Reduce this if computational power is limited. Click 'Register' to begin.
- 86) After successful completion of the first step, the 'Resample and Save Combined Image' button will become available. Click and wait for the progress bar to complete.
- 87) There is a final option to generate a correlation matrix as a PDF for quantitative assessment of the registration. Check the channel box and then click 'Compute Correlations Before and After Registration'.
- 88) Open the output file in Imaris. The registered image of all panels with channel information should be present and is now ready for further analysis or publication.
- 89) Be patient when opening the registered file for the first time. It can take 20-30 minutes to view a typical 6 cycle 20 GB dataset.
- 90) Immediately save the file after initial opening to speed up subsequent viewing.

Box 1 – Tissue Specific Dissection, Grossing, and Orientation

Individual tissues must be prepared differently to ensure correct orientation and preservation during sectioning. For the tissues highlighted in Figure 1, use the following approaches.

Procedure

1. Tissue Dissection and Grossing
 - a. Bowel: First, pour 4% molten agarose (wt/vol) dissolved in PBS into 6 well plates, covering each well with 1-1.5 ml of agarose. Allow to harden for 20 minutes. Open the bowel—opposite the mesentery or a given lesion of interest—along its entire length using scissors. Once open, rinse any residual fecal material from the mucosal surface using a stream of PBS. Cut thin strips from the opened bowel, spanning from the mucosa to the serosa, as shown in Figure 1. Pin the bowel flat onto the hardened agarose surface using 30G needles and immediately proceed to tissue processing.
 - b. Skin: These samples often curl and are difficult to orient. Shape into 1 cm x 1 cm x 3-5 mm squares and immediately proceed to tissue processing.
 - c. Lymph nodes: Carefully remove excess perinodal fat with fine forceps. Small gastric lymph nodes can be kept whole, but large lymph nodes should be cut at 2-3 mm intervals perpendicular to the longest plane.
 - d. Wedge resections (liver, kidney, spleen): Cut specimens into thin sections (less than 3-5 mm in thickness).
 - e. Other tissues: Consult with a pathologist and the emerging Common Coordinate Framework³⁶ to enable relating the processed image data to tissue anatomy. Use the suggestions above for sample preparation to maintain physical integrity and effective, rapid fixation.
2. Tissue Orientation in OCT medium
 - a. Bowel: Use a dissecting microscope and light source to aid in orienting the tissue for a longitudinal cross section.
 - b. Skin: Position appropriately for a complete cross section perpendicular to the surface of the tissue.
 - c. Lymph nodes: Orient to obtain sections along the sagittal plane.
 - d. Wedge resections (liver, kidney, spleen): Identify the smooth capsule and position the sample to allow sections perpendicular to this surface.

Box 2 – Channel Dye Separation

Dye separation is an approach to separate fluorochromes with overlapping fluorescence spectra in multiplexed experiments, so the signals can be correctly ascribed to the markers they originate from. We recommend using the Channel Dye Separation module of the Leica LAS X software. If Leica LAS X software is not available, use an open-source alternative for spectral unmixing, e.g. ImageJ plugins^{52,53} (<https://www.youtube.com/watch?v=W90qs0J29v8>).

Procedure

1. Begin by creating single color controls using reference antibodies conjugated to the same fluorophores present in IBEX tissue panels, e.g., Hoechst, CD20 AF488, CD21 AF532, CD31 PE, CD3 iF594, CD163 AF647, Ki-67 AF700).
2. Acquire single labeled tissue sections (e.g., CD20 AF488 or CD31 PE) using the same acquisition parameters employed for IBEX imaging.
3. Following acquisition of single-color control images, perform Channel Dye Separation in the LAS X Dye Separation module by selecting reference regions corresponding to positive signal for each channel (e.g., 7 channels in the above example).
4. Apply the unmixing “matrix” to all images using the Automatic Dye Separation algorithm of the Leica LAS X software. This tool uses a cluster-based analysis algorithm to vectorize the gray levels within the image and separate them into clusters for removal of crosstalk.

Troubleshooting

Steps	Problem	Possible Reason	Solution
8-11, 39-40	Tissue lifts during IBEX imaging	Insufficient chrome alum gelatin coating	Repeat with sufficient volume and coverage
		Tissue not sectioned completely flat onto the imaging substrate	Repeat, ensuring the tissue does not roll or fold during sectioning
		Chrome alum gelatin adhesive has expired	Check expiration date and replace with new bottle
		Prepared tissue sections are too old	Image samples within 1-2 days for optimal results
16-18, 48	No or poor antibody immunolabeling	Unsuitable antibody clone or incompatible antigen retrieval conditions	Validate all antibodies first using serial, conventional imaging approaches
		Insufficient concentration of antibody	Increase the $\mu\text{g/ml}$ of antibody employed
		Epitope is potentially sensitive to LiBH_4 or sterically hindered by antibodies present in earlier cycles	Move antibody to an earlier cycle or substitute with an alternative clone
3-7	High tissue autofluorescence	Tissue source and sample format high in autofluorescence, e.g. FFPE or liver tissue	Preserve tissue samples according to fixed frozen method described here. For FFPE tissues, carefully design panels with fluorophores with high quantum yields and utilize microscopes with narrow excitation/emission. See Table S5 in Hickey et al., for additional strategies ¹⁹ .
50-52	ARIA fails to prime or achieve set flow rate	Tubes or connections may be loose allowing air entry	Tighten all tubes and connection points
66-67	RC-21B imaging chamber leaks fluid	Inadequate vacuum grease	Make sure the vacuum grease forms a continuous ring without gaps
		Outflow blockage	Clean the outflow port and ensure no vacuum grease is occluding it
66	Excessive air in the imaging chamber	Uneven filling during tissue rehydration	Gently loosen the chamber from the stage insert and tilt so the air shifts to the perfusion outlet port
76	Excessive air in the imaging chamber	Bubble formation during LiBH_4 treatment	Periodically aspirate air as needed using a tuberculin syringe via the secondary inlet port
16-18, 48	Non-specific immunolabeling or fluorescent debris collecting on the tissue	Precipitated or unbound fluorophore aggregates	Use an alternative antibody from a different vendor, always spin down antibodies with a centrifuge for 30 seconds before preparing panels, and wash tissue more extensively after labeling
20, 57	Loss of image in regions or image distortion.	Insufficient immersion oil	Apply ample amounts of immersion oil to the coverslip and microscope objective
26-31, 64, 76	Incomplete fluorophore inactivation	LiBH_4 was no longer active	Always use the solution within 4 hours
26-31, 48, 76	Incomplete fluorophore inactivation resulting in left-over signal in subsequent cycle	High antibody concentration for an abundant marker	Use properly titrated antibodies, place dim markers in earlier cycles, increase duration of fluorophore inactivation to 20 minutes for secondary antibodies used in automated IBEX protocol, and, if needed, threshold dim signal using image processing software post-acquisition.
25, 55	Spectral overlap of fluorescent signals between channels	Dye Separation is required	Use Dye Separation in LAS X software or equivalent software with appropriate control slides (Box 2). Use narrow bandpass filters where available
78-90	Registration software failure	2D vs 3D settings incorrect	Under Advanced Settings check that the correct options are selected to match the dataset

Timing

- Steps 1-2, tissue grossing: 2-3 hours
- Steps 3-7, tissue processing: 2 days
- Steps 8-38 Manual IBEX option: Total ~28.5 hours
 - Steps 8-11, manual IBEX sample preparation: 2.5 hours
 - Steps 12-38, manual IBEX iterative imaging: interventions and wait time (~10 hours), total experimental time (26 hours) for a 24-plex dataset with the following properties: 3 mm², 4 cycle, 8 μm z-stack
- Steps 39-77 Automated IBEX option: Total ~19 hours
 - Steps 39-40, automated IBEX sample preparation: 2-3.5 hours
 - Steps 41-62, automated IBEX chamber assembly and solution preparation: 1 hour

- Steps 63-77, automated IBEX iterative imaging: interventions and wait time (40 minutes), total experimental time (14 hours) for a 24-plex dataset with the following properties: 3 mm², 6 cycle, 1 z-slice
- Steps 78-90, image post-processing: 45 minutes

Anticipated results

Both IBEX methods generate high quality, multiplexed imaging data with the following attributes based on the acquisition settings described here: i) image resolution of 0.284 (manual) or 0.160 μm (automated) in x-y, ii) 8-bit (manual) or 16-bit (automated) dynamic range, iii) tiled regions of interest >9 mm², and iv) total time for an equivalent 24-plex dataset of 26 (manual, 4 cycle, 8 μm z-stack) or 14 hours (automated, 6 cycle, single z-slice). These properties are distinguishing, as other imaging modalities may require 27 hours to acquire a 1 mm² area at a resolution of 0.260 μm ¹⁶. We provide here representative datasets obtained using the manual IBEX method for a wide range of human tissues including the mesenteric lymph node (38-plex, 9 cycles), spleen (25-plex, 4 cycles), and liver (22-plex, 4 cycles) (Figure 3). Using the automated IBEX protocol, the following human fixed frozen tissues were profiled: mesenteric lymph node (24-plex, 6 cycles), jejunum (24-plex, 6 cycles), and skin (19-plex, 5 cycles), a very challenging tissue due to its delicate structure and high background autofluorescence (Figure 4a-c). Additionally, we demonstrate an application of the automated IBEX method for imaging human kidney FFPE tissues (16-plex, 5 cycles) (Figure 4d). Importantly, the cycle and marker numbers presented here are provided as a proof-of-concept and do not represent a technical limitation (see Radtke *et al.*, for IBEX imaging exceeding 65 parameters²³). Cell-cell alignment across imaging cycles is typical and, importantly, needed for visualizing and quantifying complex cell types *in situ* as phenotypic markers are frequently distributed over multiple cycles. IBEX-generated images are compatible with established methods for analyzing high dimensional imaging data including the open source, computational histology topography cytometry analysis toolbox (histoCAT)⁵⁴, as previously demonstrated²³.




Figure 1. Overview of tissue grossing, sample preparation, IBEX protocols, and image registration workflow.

Specimens are first prepared using established tissue grossing protocols (Steps 1-2, Box 1, 2-3 hours). For the jejunum and skin samples, tissues are enlarged to show detail but do not reflect their actual size within the molds. Following sample preparation, tissues can be preserved as FFPE tissues (not shown) or as fixed frozen samples (Steps 3-7, 2 days). High content imaging is performed using the manual (Steps 8-38, 2-4 days) or automated (Steps 39-77, 18 hours) IBEX method, consisting of iterative cycles of antibody labeling, imaging,

and fluorophore inactivation with LiBH_4 . IBEX-generated images are then processed and aligned using SimpleITK open source software (Steps 78-90, 45 minutes).




Figure 2. Schematic overview of automated IBEX protocol.

(a) The automated IBEX protocol uses a compact microfluidics system that delivers multiple solutions to an imaging chamber placed on an inverted microscope stage. Fluids are pushed through the system with an air compressor unit and delivered to the imaging chamber based on signals coordinated by the chip (2-switch). The inverted microscope and fluidics device send and receive TTL pulses using precise timings established by interfaced control software. (b) Samples are sectioned onto coated coverslips and assembled into a closed bath imaging chamber. Following assembly, the imaging chamber is secured to a magnetic platform and mounted onto the microscope stage. Schematic demonstrates the multiple components of the overall sample preparation from top (1) to bottom (5). Fluid (purple shading) enters the chamber via the perfusion inlet port, collects in the bath, and exits by the perfusion outlet port that is attached to a vacuum line (not pictured). (c) Automated IBEX consists of: 1) nuclear labeling with Hoechst, 2) antibody labeling for 1 hour at 37°C using a heated microscope stage, 3) imaging region(s) of interest, 4) bleaching with LiBH_4 , and 5) repeating steps 2-4 until the desired number of parameters is achieved, typically 12 hours for a 6 cycle, 25-plex experiment.




Figure 3. Representative images of manual IBEX method in human tissues.

(a) Confocal images from a human mesenteric LN (9 cycles, 32 of 38 parameters shown). Scale bar is 200 µm (left), 25 µm (insets). (b) Confocal images from human spleen (4 cycles, 24 of 25 parameters shown). Scale bar is 200 µm (left), 25 µm (insets). Glycophorin A (Glyco A), Lumican (Lum), and Vimentin (Viment). (c) Confocal images from human liver (4 cycles, 11 of 22 parameters shown). Scale bar is 200 µm (left), 50 µm (insets). Glutamine synthetase (GS).




Figure 4. Representative images of automated IBEX method in human tissues. (a) Images from a human mesenteric LN (6 cycles, 23 of 24 parameters shown). Scale bar is 200 μ m (left), 50 μ m (insets). (b) Images from human jejunum (6 cycles, 16 of 24 parameters shown). Scale bar is 200 μ m (left), 50 μ m (cyan box), 25 μ m (red box). (c) Images from human skin (5 cycles, 15 of 19 parameters shown). Scale bar is 200 μ m (left), 25 μ m (insets). Keratin 10 (K10), Keratin 14 (K14). (d) Images from FFPE kidney section (5 cycles, 10 of 16 parameters shown). Scale bar is 200 μ m (left), 50 μ m (cyan box), 25 μ m (red box).

Author contributions statement

A.J.R., C.J.C., and R.N.G. wrote the manuscript. A.J.R., C.J.C., H.I., and R.T.B. designed and executed the experiments. Z.R.Y. and B.L. developed image analysis software. L.Y. designed figures 1 and 2 and A.J.R. designed figures 3 and 4. J.M. integrated the Leica microscope with the fluidics device. A.G., J.K., E.S., N.T., J.C., D.J., J.D., and J.M.H. provided technical insight, reagents, and tissues. All authors offered their guidance for the development and optimization of the workflows.

Acknowledgements

This research was supported by the Intramural Research Program of the NIH, NIAID and NCI. This research was also partially supported by a Research Collaboration Agreement (RCA) between NIAID and BioLegend, Inc. (RCA# 2020-0333) and the Chan Zuckerberg Initiative Human Cell Atlas Thymus Seed Network. C.J.C is supported as a UK-US Fulbright Scholar and Fight for Sight Research Scholar. Z.Y. and B.C.L. are supported by the BCBB Support Services Contract HHSN316201300006W/HHSN27200002 to Medical Science & Computing, LLC. D.J. is supported by the grant of the European Research Council (ERC); European Consolidator Grant, XHale (Reference #771883). We would like to thank Robert Pelletier and Mark Aruda from Fluigent for their sterling assistance with the ARIA fluidics device. We are extremely grateful for the technical support provided by George Portugal, Emily Cox, and Ed Buck from Harvard Apparatus. We thank Dr. Stefania Pittaluga for her assistance with tissue grossing and orientation. We are appreciative of Drs. Giorgio Cattoretti and Maddalena Bolognesi for sharing their insights on fluorophore inactivation with sodium borohydride.

Competing interests

Joshua Croteau is an employee of Biolegend, Inc. and James Marr is an employee of Leica Microsystems, Inc.

References

- 1 Regev, A. *et al.* The Human Cell Atlas. *Elife* **6**, doi:10.7554/eLife.27041 (2017).
- 2 Snyder, M. P. *et al.* The human body at cellular resolution: the NIH Human Biomolecular Atlas Program. *Nature* **574**, 187-192, doi:10.1038/s41586-019-1629-x (2019).
- 3 Börner, K. *et al.* Anatomical Structures, Cell Types, and Biomarkers Tables Plus 3D Reference Organs in Support of a Human Reference Atlas. *bioRxiv*, 2021.2005.2031.446440, doi:10.1101/2021.05.31.446440 (2021).
- 4 Schubert, W. *et al.* Analyzing proteome topology and function by automated multidimensional fluorescence microscopy. *Nat Biotechnol* **24**, 1270-1278, doi:10.1038/nbt1250 (2006).
- 5 Schubert, W. Topological proteomics, toponomics, MELK-technology. *Adv Biochem Eng Biotechnol* **83**, 189-209, doi:10.1007/3-540-36459-5_8 (2003).
- 6 Gerdes, M. J. *et al.* Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. *Proc Natl Acad Sci U S A* **110**, 11982-11987, doi:10.1073/pnas.1300136110 (2013).
- 7 Lin, J. R., Fallahi-Sichani, M. & Sorger, P. K. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method. *Nat Commun* **6**, 8390, doi:10.1038/ncomms9390 (2015).
- 8 Lin, J. R. *et al.* Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. *Elife* **7**, doi:10.7554/eLife.31657 (2018).

- 9 Adams, D. L., Alpaugh, R. K., Tsai, S., Tang, C. M. & Stefansson, S. Multi-Phenotypic subtyping of circulating tumor cells using sequential fluorescent quenching and restaining. *Sci Rep* **6**, 33488, doi:10.1038/srep33488 (2016).
- 10 Tsujikawa, T. *et al.* Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. *Cell Rep* **19**, 203-217, doi:10.1016/j.celrep.2017.03.037 (2017).
- 11 Gut, G., Herrmann, M. D. & Pelkmans, L. Multiplexed protein maps link subcellular organization to cellular states. *Science* **361**, doi:10.1126/science.aar7042 (2018).
- 12 Goltsev, Y. *et al.* Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging. *Cell* **174**, 968-981 e915, doi:10.1016/j.cell.2018.07.010 (2018).
- 13 Saka, S. K. *et al.* Immuno-SABER enables highly multiplexed and amplified protein imaging in tissues. *Nature Biotechnology* **37**, 1080-1090, doi:10.1038/s41587-019-0207-y (2019).
- 14 Angelo, M. *et al.* Multiplexed ion beam imaging of human breast tumors. *Nat Med* **20**, 436-442, doi:10.1038/nm.3488 (2014).
- 15 Giesen, C. *et al.* Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. *Nat Methods* **11**, 417-422, doi:10.1038/nmeth.2869 (2014).
- 16 Taube, J. M. *et al.* The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. *J Immunother Cancer* **8**, doi:10.1136/jitc-2019-000155 (2020).
- 17 Tan, W. C. C. *et al.* Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. *Cancer Commun (Lond)* **40**, 135-153, doi:10.1002/cac2.12023 (2020).
- 18 Bodenmiller, B. Multiplexed Epitope-Based Tissue Imaging for Discovery and Healthcare Applications. *Cell Syst* **2**, 225-238, doi:10.1016/j.cels.2016.03.008 (2016).
- 19 Hickey, J. *et al.* Spatial mapping of protein composition and tissue organization: a primer for multiplexed antibody-based imaging. [arXiv:2107.07953](https://arxiv.org/abs/2107.07953) (2021).
- 20 Schürch, C. M. *et al.* Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. *Cell* **182**, 1341-1359.e1319, doi:<https://doi.org/10.1016/j.cell.2020.07.005> (2020).
- 21 Keren, L. *et al.* A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. *Cell* **174**, 1373-1387 e1319, doi:10.1016/j.cell.2018.08.039 (2018).
- 22 Jackson, H. W. *et al.* The single-cell pathology landscape of breast cancer. *Nature* **578**, 615-620, doi:10.1038/s41586-019-1876-x (2020).
- 23 Radtke, A. J. *et al.* IBEX: A versatile multiplex optical imaging approach for deep phenotyping and spatial analysis of cells in complex tissues. *Proc Natl Acad Sci U S A* **117**, 33455-33465, doi:10.1073/pnas.2018488117 (2020).
- 24 Gola, A. *et al.* Commensal-driven immune zonation of the liver promotes host defence. *Nature* **589**, 131-136, doi:10.1038/s41586-020-2977-2 (2021).
- 25 Lowekamp, B. C., Chen, D. T., Ibanez, L. & Blezek, D. The Design of SimpleITK. *Front Neuroinform* **7**, 45, doi:10.3389/fninf.2013.00045 (2013).
- 26 Yaniv, Z., Lowekamp, B. C., Johnson, H. J. & Beare, R. SimpleITK Image-Analysis Notebooks: a Collaborative Environment for Education and Reproducible Research. *J Digit Imaging* **31**, 290-303, doi:10.1007/s10278-017-0037-8 (2018).
- 27 Vaughan, J. C., Jia, S. & Zhuang, X. Ultrabright photoactivatable fluorophores created by reductive caging. *Nat Methods* **9**, 1181-1184, doi:10.1038/nmeth.2214 (2012).
- 28 Bolognesi, M. M. *et al.* Multiplex Staining by Sequential Immunostaining and Antibody Removal on Routine Tissue Sections. *J Histochem Cytochem* **65**, 431-444, doi:10.1369/0022155417719419 (2017).
- 29 Murray, E. *et al.* Simple, Scalable Proteomic Imaging for High-Dimensional Profiling of Intact Systems. *Cell* **163**, 1500-1514, doi:10.1016/j.cell.2015.11.025 (2015).
- 30 Baschong, W., Suetterlin, R. & Laeng, R. H. Control of autofluorescence of archival formaldehyde-fixed, paraffin-embedded tissue in confocal laser scanning microscopy

- (CLSM). *J Histochem Cytochem* **49**, 1565-1572, doi:10.1177/002215540104901210 (2001).
- 31 Hounsell, E. F., Pickering, N. J., Stoll, M. S., Lawson, A. M. & Feizi, T. The effect of mild alkali and alkaline borohydride on the carbohydrate and peptide moieties of fetuin. *Biochem Soc Trans* **12**, 607-610, doi:10.1042/bst0120607 (1984).
- 32 Yakulis, V., Schmale, J., Costea, N. & Hellerp. Production of Fc fragments of IgM. *J Immunol* **100**, 525-529 (1968).
- 33 Corrodi, H., Hillarp, N. A. & Jonsson, G. Fluorescence Methods for the Histochemical Demonstration of Monoamines. 3. Sodium Borohydride Reduction of the Fluorescent Compounds as a Specificity Test. *J Histochem Cytochem* **12**, 582-586, doi:10.1177/12.8.582 (1964).
- 34 Nystrom, R. F., Chaikin, S. W. & Brown, W. G. Lithium Borohydride as a Reducing Agent. *J Am Chem Soc* **71**, 3245-3246, doi:DOI 10.1021/ja01177a514 (1949).
- 35 Westra, W. H. *Surgical Pathology Dissection: An Illustrated Guide*. (Springer, 2003).
- 36 Rood, J. E. *et al.* Toward a Common Coordinate Framework for the Human Body. *Cell* **179**, 1455-1467, doi:10.1016/j.cell.2019.11.019 (2019).
- 37 Lester, S. C. *Manual of Surgical Pathology (Surgical Pathology)*. (W B Saunders Company, 2010).
- 38 Jonigk, D., Modde, F., Bockmeyer, C. L., Becker, J. U. & Lehmann, U. Optimized RNA extraction from non-deparaffinized, laser-microdissected material. *Methods Mol Biol* **755**, 67-75, doi:10.1007/978-1-61779-163-5_5 (2011).
- 39 Gerner, M. Y., Kastenmuller, W., Ifrim, I., Kabat, J. & Germain, R. N. Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes. *Immunity* **37**, 364-376, doi:10.1016/j.immuni.2012.07.011 (2012).
- 40 Kastenmuller, W., Torabi-Parizi, P., Subramanian, N., Lammermann, T. & Germain, R. N. A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. *Cell* **150**, 1235-1248, doi:10.1016/j.cell.2012.07.021 (2012).
- 41 Mao, K. *et al.* Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism. *Nature* **554**, 255-259, doi:10.1038/nature25437 (2018).
- 42 Baptista, A. P. *et al.* The Chemoattractant Receptor Ebi2 Drives Intranodal Naive CD4(+) T Cell Peripheralization to Promote Effective Adaptive Immunity. *Immunity* **50**, 1188-1201 e1186, doi:10.1016/j.immuni.2019.04.001 (2019).
- 43 Uderhardt, S., Martins, A. J., Tsang, J. S., Lammermann, T. & Germain, R. N. Resident Macrophages Cloak Tissue Microlesions to Prevent Neutrophil-Driven Inflammatory Damage. *Cell* **177**, 541-555 e517, doi:10.1016/j.cell.2019.02.028 (2019).
- 44 Petrovas, C. *et al.* Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. *Science Translational Medicine* **9**, doi:ARTN eaag228510.1126/scitranslmed.aag2285 (2017).
- 45 Sayin, I. *et al.* Spatial distribution and function of T follicular regulatory cells in human lymph nodes. *J Exp Med* **215**, 1531-1542, doi:10.1084/jem.20171940 (2018).
- 46 Radtke, A. J. *et al.* Lymph-node resident CD8alpha+ dendritic cells capture antigens from migratory malaria sporozoites and induce CD8+ T cell responses. *PLoS Pathog* **11**, e1004637, doi:10.1371/journal.ppat.1004637 (2015).
- 47 Srivastava, S., Ghosh, S., Kagan, J., Mazurchuk, R. & National Cancer Institute's, H. I. The Making of a PreCancer Atlas: Promises, Challenges, and Opportunities. *Trends Cancer* **4**, 523-536, doi:10.1016/j.trecan.2018.06.007 (2018).
- 48 Uhlen, M. *et al.* Proteomics. Tissue-based map of the human proteome. *Science* **347**, 1260419, doi:10.1126/science.1260419 (2015).
- 49 Du, Z. *et al.* Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. *Nat Protoc* **14**, 2900-2930, doi:10.1038/s41596-019-0206-y (2019).
- 50 Thevenaz, P., Ruttimann, U. E. & Unser, M. A pyramid approach to subpixel registration based on intensity. *IEEE Trans Image Process* **7**, 27-41, doi:10.1109/83.650848 (1998).

- 51 Guizar-Sicairos, M., Thurman, S. T. & Fienup, J. R. Efficient subpixel image registration algorithms. *Opt Lett* **33**, 156-158, doi:10.1364/ol.33.000156 (2008).
- 52 McRae, T. D., Oleksyn, D., Miller, J. & Gao, Y. R. Robust blind spectral unmixing for fluorescence microscopy using unsupervised learning. *Plos One* **14**, doi:ARTN e0225410.1371/journal.pone.0225410 (2019).
- 53 Neher, R. A. *et al.* Blind source separation techniques for the decomposition of multiply labeled fluorescence images. *Biophys J* **96**, 3791-3800, doi:10.1016/j.bpj.2008.10.068 (2009).
- 54 Schapiro, D. *et al.* histoCAT: analysis of cell phenotypes and interactions in multiplex image cytometry data. *Nat Methods* **14**, 873-876, doi:10.1038/nmeth.4391 (2017).

Supplementary Information

Extended Data Figure 1. Critical steps in the manual IBEX protocol.


Extended Data Figure 2. Equipment and assembly of imaging chamber for automated IBEX protocol.

Table S1. Time and method used to bleach fluorescently conjugated antibodies and dyes.

Table S2. IBEX panels for human organs.


Table S3. Recommendations for optimal antibody and fluorophore pairing for IBEX panel design.

Table S4. Estimated costs for IBEX implementation.



Extended Data Figure 1. Critical steps in the manual IBEX protocol.

(a) Photo depicting central placement of tissue within a 2-well chambered coverglass. Glass surface is coated with chrome gelatin alum (invisible when fully dry). (b) Picture of small bubbles that form during successful LiBH_4 treatment. (c) Visual instructions on how to match unique nuclear shapes (Hoechst in yellow, blue box) across the imaging volumes. The left image corresponds to a live image in the Leica LAS X Navigator software. The right image corresponds to the image captured from the previous IBEX cycle. Red circles indicate that the described alignment procedure is being done at the first z slice ('Begin') of the z-stack.



Extended Data Figure 2. Equipment and assembly of imaging chamber for automated IBEX protocol.

(a) Tissues are sectioned onto coated 22x22 mm square coverslips and assembled into the RC-21B Large Closed Bath Imaging Chamber. Top view of imaging chamber placed into PM-2 Platform for Series 20 chambers without (b) and with (c) magnetic platform clamp. (d) Equipment footprint of automated IBEX set up; Fluigent Low Pressure Generator (FLPG). (e) Complete assembly of PM-2 Platform with RC-21B chamber onto SA20-PL Series 20 stage adapter. Fluid inlet and vacuum outlet highlight the fluid path. Heating electrodes are attached to the top and bottom of the platform using metal prongs that must be bent by user to allow placement into the stage. Temperature probe is inserted into small hole at top of platform to maintain 37°C for the duration of the protocol.

Tables S1-S4

Table S1. Time and method used to bleach fluorescently conjugated antibodies and dyes.

Antibody	Clone	RRID	Vendor	Cat No.	Species reactivity	Isotype	Dilution	Time to Bleach (Minutes)	
								LiBH ₄	LiBH ₄ + Light
β-3 Tubulin BV421	AA10	AB_2632699	BioLegend	657412	Human, Mouse	Mouse IgG2a, κ	1:200	-	<15
β-3 Tubulin AF488	TUJ1	AB_2564757	BioLegend	801203	Human, Mouse	Mouse IgG2a, κ	1:50	<15	-
β-3 Tubulin AF532	AA10	NA	BioLegend	Custom	Human, Mouse	Mouse IgG2a, κ	1:100	<15	-
ACE2	-	AB_355722	R&D	AF933	Human	Goat IgG	1:50	-	-
B220 BV421	RA3-6B2	AB_2562905	BioLegend	103251	Mouse	Rat IgG2a, κ	1:400	-	<15
B220 BV510	RA3-6B2	AB_2650679	BioLegend	103248	Mouse	Rat IgG2a, κ	1:300	-	<15
B220 AF488	RA3-6B2	AB_396781	BD Biosciences	557669	Mouse	Rat IgG2a, κ	1:400	<15	-
B220 AF532	RA3-6B2	AB_11218492	Thermo	58-0452-82	Mouse	Rat IgG2a, κ	1:50	<15	-
B220 PE	RA3-6B2	AB_394620	BD Biosciences	553090	Mouse	Rat IgG2a, κ	1:400	<15	-
B220 eF570	RA3-6B2	AB_2573598	Thermo	41-0452-80	Mouse	Rat IgG2a, κ	1:200	<15	-
B220 eF615	RA3-6B2	AB_10852702	Thermo	42-0452-82	Mouse	Rat IgG2a, κ	1:200	>120	-
B220 AF647	RA3-6B2	AB_389330	BioLegend	103226	Mouse	Rat IgG2a, κ	1:400	<15	-
B220 AF700	RA3-6B2	AB_493717	BioLegend	103232	Mouse	Rat IgG2a, κ	1:50	<15	-
BCL2 AF647	100	AB_2563279	BioLegend	658705	Human	Mouse IgG ₁	1:25	<15	-
Bcl6 AF647	K112-91	AB_10898007	BD Biosciences	561525	Human, Mouse	Mouse IgG ₁ , κ	1:25	<15	-
Cathepsin L	204101	AB_2087829	R&D	MAB-9521	Human	Rat IgG2a	1:50	-	-
CD1c PE	L161	AB_1089000	BioLegend	331506	Human	Mouse IgG ₁ , κ	1:50	<15	-
CD1d PE	1B1	AB_2073521	BD Biosciences	553846	Mouse	Rat IgG2b, κ	1:100	<15	-
CD3 BV421	17A2	AB_2562553	BioLegend	100228	Mouse	Rat IgG2b, κ	1:400	-	<15
CD3 BV510	17A2	AB_2562555	BioLegend	100234	Mouse	Rat IgG2b, κ	1:50	-	<15
CD3 AF488	17A2	AB_389301	BioLegend	100210	Mouse	Rat IgG2b, κ	1:200	<15	-
CD3 AF532	17A2	AB_11220474	Thermo	58-0032-80	Mouse	Rat IgG2b, κ	1:50	<15	-
CD3 PE	17A2	AB_312662	BioLegend	100205	Mouse	Rat IgG2b, κ	1:200	<15	-
CD3 AF594	17A2	AB_2563427	BioLegend	100240	Mouse	Rat IgG2b, κ	1:400	>120	-
CD3 AF647	17A2	AB_396912	BD Biosciences	557869	Mouse	Rat IgG2b, κ	1:400	<15	-
CD3 AF532	UCHT1	AB_11218675	Thermo	58-0038-42	Human	Mouse IgG ₁ , κ	1:50	<15	-
CD3 AF594	UCHT1	AB_2563236	BioLegend	300446	Human	Mouse IgG ₁	1:200	>120	-
CD3 iF594	UCHT1	NA	Caprico Biotechnologies	1053134	Human	Mouse IgG ₁	1:50	<15	-
CD4 BV421	GK1.5	AB_2562557	BioLegend	100443	Mouse	Rat IgG2b, κ	1:200	-	<15
CD4 BV510	GK1.5	AB_2564587	BioLegend	100449	Mouse	Rat IgG2b, κ	1:50	-	<15
CD4 PE	GK1.5	AB_395014	BD Biosciences	553730	Mouse	Rat IgG2b, κ	1:200	<15	-
CD4 AF594	GK1.5	AB_2563182	BioLegend	100446	Mouse	Rat IgG2b, κ	1:200	>120	-
CD4 AF488	RM4-5	AB_396779	BD Biosciences	557667	Mouse	Rat IgG2a, κ	1:100	<15	-
CD4 AF532	RM4-5	AB_11219484	Thermo	58-0042-80	Mouse	Rat IgG2a, κ	1:50	<15	-
CD4 eF570	RM4-5	AB_2573595	Thermo	41-0042-82	Mouse	Rat IgG2a, κ	1:100	<15	-
CD4 AF532	RPA-T4	AB_2802361	Thermo	58-0049-42	Human	Mouse IgG ₁ , κ	1:25	<15	-
CD4 AF647	RPA-T4	AB_389333	BioLegend	300520	Human	Mouse IgG ₁ , κ	1:100	<15	-
CD4 AF700	RPA-T4	AB_493743	BioLegend	300526	Human	Mouse IgG ₁ , κ	1:25	<15	-
CD8 BV421	53-6.7	AB_11204079	BioLegend	100738	Mouse	Rat IgG2a, κ	1:200	-	<15
CD8 BV510	53-6.7	AB_2563057	BioLegend	100752	Mouse	Rat IgG2a, κ	1:200	-	<15

CD8 AF488	53-6.7	AB_389304	BioLegend	100723	Mouse	Rat IgG2a, k	1:200	<15	-
CD8 PE	53-6.7	AB_394570	BD Biosciences	553032	Mouse	Rat IgG2a, k	1:400	<15	-
CD8 AF594	53-6.7	AB_2563237	BioLegend	100758	Mouse	Rat IgG2a, k	1:200	>120	-
CD8 AF647	53-6.7	AB_389326	BioLegend	100724	Mouse	Rat IgG2a, k	1:200	<15	-
CD8 AF488	SK1	AB_10549301	BioLegend	344716	Human	Mouse IgG ₁ , k	1:50	<15	-
CD10 PE	FR4D11	NA	Caprico Biotechnologies	103926	Human	Mouse IgG ₁ , k	1:50	<15	-
CD10	-	AB_354652	R&D	AF1182	Human	Goat IgG	1:200	-	-
CD11b FITC	5C6	AB_2538034	Thermo	MA5-16529	Mouse	Rat IgG2b	1:100	<30	-
CD11b PE	5C6	AB_323678	Bio-Rad	MCA711PE	Mouse	Rat IgG2b	1:100	<15	-
CD11b AF488	M1/70	AB_389305	BioLegend	101217	Mouse	Rat IgG2b, k	1:100	<15	-
CD11c AF488	N418	AB_10373244	Thermo	MCD11c20	Mouse	Hamster IgG	1:50	<15	-
CD11c AF594	N418	AB_2563323	BioLegend	117346	Mouse	Hamster IgG	1:50	>120	-
CD11c AF647	N418	AB_389328	BioLegend	117312	Mouse	Hamster IgG	1:100	<15	-
CD11c AF700	B-Ly6	AB_10612006	BD Biosciences	561352	Human	Mouse IgG ₁ , k	1:25	<15	-
CD15	MMA	AB_400298	BD Biosciences	347420	Human	Mouse IgM	1:50	-	-
CD20 AF488	L26	AB_10734358	Thermo	53-0202-82	Human	Mouse IgG2b, k	1:200	<15	-
CD20 eF615	L26	AB_10853517	Thermo	42-0202-82	Human	Mouse IgG2b, k	1:200	>120	-
CD20 eF660	L26	AB_11150959	Thermo	50-0202-82	Human	Mouse IgG2b, k	1:200	<15	-
CD21 Pacific Blue	7E9	AB_2085159	BioLegend	123413	Mouse	Rat IgG2a, k	1:200	<15	-
CD21 AF488	Bu32	NA	BioLegend	Custom	Human	Mouse IgG ₁ , k	1:100	<15	-
CD21 AF532	Bu32	NA	BioLegend	Custom	Human	Mouse IgG ₁ , k	1:400	<15	-
CD23 AF647	B3B4	AB_493479	BioLegend	101611	Mouse	Rat IgG2a, k	1:50	<15	-
CD23 AF532	EBVCS-5	NA	BioLegend	Custom	Human	Mouse IgG ₁ , k	1:25	<15	-
CD25 AF488	PC61.5	AB_763472	Thermo	53-0251-82	Mouse	Rat IgG1, λ	1:50	<15	-
CD25 AF647	M-A251	AB_2563587	BioLegend	356127	Human	Mouse IgG ₁ , k	1:50	<15	-
CD31 AF488	MEC13.3	AB_2161031	BioLegend	102514	Mouse	Rat IgG2a, k	1:100	<15	-
CD31 PE	MEC13.3	AB_394819	BD Biosciences	553373	Mouse	Rat IgG2a, k	1:200	<15	-
CD31 AF594	MEC13.3	AB_2563319	BioLegend	102520	Mouse	Rat IgG2a, k	1:100	>120	-
CD31 AF647	MEC13.3	AB_2161029	BioLegend	102516	Mouse	Rat IgG2a, k	1:100	<15	-
CD31 PE	WM59	AB_314332	BioLegend	303106	Human	Mouse IgG ₁ , k	1:100	<15	-
CD31 AF700	WM59	AB_2566326	BioLegend	303133	Human	Mouse IgG ₁ , k	1:25	<15	-
CD34 PE	QBEND/10	AB_11152571	Thermo	MA1-10205	Human	Mouse IgG ₁	1:50	<15	-
CD34 iF594	4H11	NA	AAT Bioquest	103400C0	Human	Mouse IgG ₁	1:25	<15	-
CD35 BV510	8C12	AB_2739889	BD Biosciences	740132	Mouse	Rat IgG2a, k	1:600	-	<15
CD35 PE	E11	AB_2292231	BioLegend	333406	Human	Mouse IgG ₁ , k	1:800	<15	-
CD38 AF700	HIT2	AB_2072781	BioLegend	303524	Human	Mouse IgG ₁ , k	1:25	<15	-
CD39 PE	A1	AB_940429	BioLegend	328208	Human	Mouse IgG ₁ , k	1:50	<15	-
CD44 AF488	IM7	AB_493679	BioLegend	103016	Human, Mouse	Rat IgG2b, k	1:100	<15	-
CD44 AF532	IM7	NA	BioLegend	Custom	Human, Mouse	Rat IgG2b, k	1:100	<15	-
CD44 AF647	IM7	AB_493681	BioLegend	103018	Human, Mouse	Rat IgG2b, k	1:100	<15	-
CD44 AF700	IM7	AB_493713	BioLegend	103026	Human, Mouse	Rat IgG2b, k	1:50	<15	-
CD45 BV421	30-F11	AB_2562559	BioLegend	103134	Mouse	Rat IgG2b, k	1:100	-	<15
CD45 BV510	30-F11	AB_2563061	BioLegend	103138	Mouse	Rat IgG2b, k	1:100	-	<15
CD45 AF488	30-F11	AB_493531	BioLegend	103122	Mouse	Rat IgG2b, k	1:200	<15	-
CD45 AF532	30-F11	AB_11218871	Thermo	58-0451-82	Mouse	Rat IgG2b, k	1:200	<15	-

CD45 AF647	30-F11	AB_493533	BioLegend	103124	Mouse	Rat IgG2b, k	1:400	<15	-
CD45 AF700	30-F11	AB_493715	BioLegend	103128	Mouse	Rat IgG2b, k	1:50	<15	-
CD45 AF532	HI30	AB_11218084	Thermo	58-0459-41	Human	Mouse IgG ₁ , k	1:50	<15	-
CD45 AF594	HI30	AB_2629599	BioLegend	304060	Human	Mouse IgG ₁ , K	1:100	>120	-
CD45 PE//Fluor594	F10-89-4	NA	Caprico Biotechnologies	1016185	Human	Mouse IgG2a, k	1:50	<15	-
CD45 iF594	F10-89-4	NA	Caprico Biotechnologies	1016136	Human	Mouse IgG2a, k	1:50	<15	-
CD49a PE	TS2/7	AB_1236441	BioLegend	328304	Human	Mouse IgG ₁ , k	1:50	<15	-
CD49a AF647	TS2/7	AB_2129242	BioLegend	328310	Human	Mouse IgG ₁ , k	1:200	<15	-
CD54 AF647	HA58	AB_2715942	BioLegend	353114	Human	Mouse IgG ₁ , k	1:50	<15	-
CD61 FITC	Y2/51	AB_2660493	Miltenyi	130-098-682	Human	Mouse IgG ₁ , k	1:25	<30	-
CD64 AF647	X54-5/7.1	AB_2566561	BioLegend	139322	Mouse	Mouse IgG ₁ , K	1:50	<15	-
CD66b iF594	G10F5	NA	Caprico Biotechnologies	1075139	Human	Mouse IgM, k	1:25	<15	-
CD66b AF647	G10F5	AB_2563171	BioLegend	305110	Human	Mouse IgM, k	1:25	<15	-
CD68 BV421	FA-11	AB_2562949	BioLegend	137017	Mouse	Rat IgG2a	1:200	-	<15
CD68 AF488	FA-11	AB_2074847	BioLegend	137011	Mouse	Rat IgG2a	1:50	<15	-
CD68 iF594	KP1	NA	Caprico Biotechnologies	1064135	Human	Mouse IgG ₁ , k	1:100	<15	-
CD68 AF647	KP1	AB_627158	Santa Cruz	sc-200060	Human	Mouse IgG ₁ , k	1:100	<15	-
CD69	-	AB_416586	R&D	AF2386	Mouse	Goat IgG	1:50	-	-
CD69 AF647	FN50	AB_528871	BioLegend	310918	Human	Mouse IgG ₁ , k	1:50	<15	-
CD94 PE	DX22	AB_314536	BioLegend	305506	Human	Mouse IgG ₁ , k	1:50	<15	-
CD103 AF488	2E7	AB_535949	BioLegend	121407	Mouse	Hamster IgG	1:100	<15	-
CD106 AF488	429	AB_493427	BioLegend	105710	Mouse	Rat IgG2a, k	1:50	<15	-
CD106 eF660	429	AB_11217676	Thermo	50-1061-80	Mouse	Rat IgG2a, k	1:50	<15	-
CD106 PE	STA	AB_314561	BioLegend	305806	Human	Mouse IgG ₁ , k	1:50	<15	-
CD117 BV421	2B8	AB_10898120	BioLegend	105827	Mouse	Rat IgG2b, k	1:50	-	<15
CD117 AF488	104D2	AB_2566221	BioLegend	313234	Human	Mouse IgG ₁ , k	1:50	<15	-
CD117 PE	104D2	AB_314983	BioLegend	313204	Human	Mouse IgG ₁ , k	1:50	<15	-
CD138 BV421	281-2	AB_11153126	BD Biosciences	562610	Mouse	Rat IgG2a, k	1:50	-	<15
CD138 AF647	281-2	AB_2566239	BioLegend	142526	Mouse	Rat IgG2a, k	1:50	<15	-
CD138 PE	MI15	AB_2561878	BioLegend	356504	Human	Mouse IgG ₁ , k	1:200	<15	-
CD138 AF647	MI15	AB_2564250	BioLegend	356523	Human	Mouse IgG ₁ , k	1:200	<15	-
CD163 PE	GH1/61	AB_1134002	BioLegend	333606	Human	Mouse IgG ₁ , k	1:300	<15	-
CD163 AF647	GH1/61	AB_2563474	BioLegend	333620	Human	Mouse IgG ₁ , k	1:100	<15	-
CD166 AF488	EPR2759	AB_2889210	Abcam	Ab197543	Human	Rabbit mAb	1:100	<15	-
CD169 FITC	3D6.112	AB_324246	Bio-Rad	MCA884F	Mouse	Rat IgG2a, k	1:50	<30	-
CD169 PE	3D6.112	AB_10915697	Biolegend	142404	Mouse	Rat IgG2a, k	1:300	<15	-
CD169 AF594	3D6.112	AB_2565620	BioLegend	142416	Mouse	Rat IgG2a, k	1:100	>120	-
CD200 BV421	Ox-90	AB_2739289	BD Biosciences	565547	Mouse	Rat IgG2a, k	1:100	-	<15
CD206 BV421	C068C2	AB_2562232	BioLegend	141717	Mouse	Rat IgG2a, k	1:100	-	<15
CD207 PE	eBioL31	AB_763453	Thermo	12-2075-80	Mouse	Rat IgG2a	1:50	<15	-
Clec9a AF488	8F9	NA	BioLegend	Custom	Human	Mouse IgG2a, k	1:25	<15	-
Collagen IV	-	AB_445160	Abcam	ab19808	Mouse	Rabbit IgG	1:200	-	-
Collagen IV	-	AB_305584	Abcam	ab6586	Human	Rabbit IgG	1:200	-	-
CXCL12 AF532	79018	-	R&D	MAB350-500 (Unconjugated)	Human	Mouse IgG ₁	1:25	<15	-
CXCL13 AF532	-	AB_355613	R&D	AF801 (Unconjugated)	Human	Goat IgG	1:25	<15	-

CXCR6 AF647	221002	NA	Novus	FAB2145R	Mouse	Rat IgG2b	1:50	<15	-
Cytokeratin AF647	C-11	AB_2563652	BioLegend	628604	Human	Mouse IgG ₁ , k	1:200	<15	-
Cytokeratin AF488	AE1/AE3	AB_2574301	Thermo	53-9003-82	Human, Mouse	Mouse IgG ₁	1:50	<15	-
Cytokeratin eF660	AE1/AE3	AB_2574301	Thermo	50-9003-82	Human, Mouse	Mouse IgG ₁	1:100	<15	-
Cytokeratin 7 AF488		AB_2728458	BioLegend	601605	Human	Rat IgG2a, k	1:50	<15	-
Cytokeratin 10 AF488	DE-K10	NA	Novus	NBP2-54402AF488	Human	Mouse IgG ₁ , k	1:200	<15	-
Cytokeratin 14	Poly9060	AB_2616962	BioLegend	906004	Human, Mouse	Chicken IgY	1:50	-	-
DCAMKL1	-	AB_873538	Abcam	Ab37994	Human, Mouse	Rabbit IgG	1:50	-	-
DC-SIGN AF647	9E9A8	AB_1186092	BioLegend	330112	Human	Mouse IgG2a, k	1:50	<15	-
DEC205 AF647	NLDC-145	AB_2137655	BioLegend	138204	Mouse	Rat IgG2a, k	1:50	<15	-
Desmin	-	AB_301744	Abcam	Ab15200	Human	Rabbit IgG	1:200	-	-
Desmin AF488	Y66	NA	Abcam	Ab185033	Human	Rabbit IgG	1:200	<15	-
E-cadherin AF647	DECMA-1	AB_2563955	BioLegend	147308	Mouse	Rat IgG1, k	1:100	<15	-
EpCAM BV510	G8.8	AB_2738075	BD Biosciences	563216	Mouse	Rat IgG2a, k	1:100	-	<15
EpCAM AF594	G8.8	AB_2563322	BioLegend	118222	Mouse	Rat IgG2a, k	1:400	>120	-
EpCAM AF647	G8.8	AB_1134101	BioLegend	118212	Mouse	Rat IgG2a, k	1:200	<15	-
EpCAM AF488	9C4	AB_756084	BioLegend	324210	Human	Mouse IgG2b, k	1:300	<15	-
EpCAM AF594	9C4	AB_2563209	BioLegend	324228	Human	Mouse IgG2b, k	1:500	>120	-
EpCAM AF647	9C4	AB_1134101	BioLegend	324212	Human	Mouse IgG2b, k	1:100	<15	-
EpCAM	-	AB_1603782	Abcam	Ab71916	Human	Rabbit IgG	1:50	-	-
F4/80 BV421	BM8	AB_11203717	BioLegend	123132	Mouse	Rat IgG2a, k	1:50	-	<15
F4/80 PE	BM8	AB_465923	Thermo	12-4801-82	Mouse	Rat IgG2a, k	1:100	<15	-
F4/80 AF647	BM8	AB_893480	BioLegend	123122	Mouse	Rat IgG2a, k	1:50	<15	-
F4/80 AF700	BM8	AB_2293450	BioLegend	123130	Mouse	Rat IgG2a, k	1:50	<15	-
Fibronectin AF532	2F4	NA	Novus	NBP2-22113AF532	Human	Mouse IgG ₁	1:25	<15	-
Fibrinogen	-	AB_10900171	Abcam	Ab118533 (Unconjugated)	Human	Sheep IgG	1:200	<15	-
Foxp3 AF488	FJK-16s	AB_763537	Thermo	53-5773-82	Mouse	Rat IgG2a, k	1:50	<15	-
Foxp3 AF532	FJK-16s	AB_11218870	Thermo	58-5773-82	Mouse	Rat IgG2a, k	1:50	<15	-
Foxp3 PE	FJK-16s	AB_465936	Thermo	12-5773-82	Mouse	Rat IgG2a, k	1:50	<15	-
Foxp3 eF570	FJK-16s	AB_11219073	Thermo	41-5773-82	Mouse	Rat IgG2a, k	1:50	<15	-
Foxp3 eF660	FJK-16s	AB_11218868	Thermo	50-5773-82	Mouse	Rat IgG2a, k	1:50	<15	-
FOXP3 eF570	236A/E7	AB_2573609	Thermo	41-4777-82	Human	Mouse IgG ₁ , k	1:25	<15	-
GL-7 PE	GL7	AB_10715834	BD Biosciences	561530	Mouse	Rat IgM, k	1:100	<15	-
Glutamine synthetase	-	AB_880241	Abcam	Ab49873	Human, Mouse	Rabbit IgG	1:200	-	-
Glycophorin	EPR8200	-	Abcam	Ab218372	Human	Rabbit IgG	1:300	-	-
gp38 AF488	8.1.1	AB_1133992	BioLegend	127405	Mouse	Hamster IgG	1:50	<15	-
HLA-DR AF488	L243	AB_493176	BioLegend	307619	Human	Mouse IgG2a, k	1:200	<15	-
HLA-DR iF594	L243	NA	Caprico Biotechnologies	1032136	Human	Mouse IgG2a, k	1:100	<15	-
Hoechst 33342	-	-	Biotium	40046		-	1:5,000	-	-
ICOS AF488	C398.4A	AB_2122584	BioLegend	313514	Human	Hamster IgG	1:25	<15	-
IgA AF555	-	AB_2794378	SouthernBiotech	1040-32	Human	Goat IgG	1:500	<15	-
IgA1 AF647	B3506B4	AB_2796658	SouthernBiotech	9130-31	Human	Mouse IgG ₁ , k	1:500	<15	-
IgA2 AF488	A9604D2	AB_2796665	SouthernBiotech	9140-30	Human	Mouse IgG ₁ , k	1:500	<15	-
IgD AF488	11-26c.2a	AB_10730619	BioLegend	405718	Mouse	Rat IgG2a, k	1:400	<15	-
IgD AF594	11-26c.2a	AB_2565572	BioLegend	405740	Mouse	Rat IgG2a, k	1:400	>120	-

IgD AF700	11-26c.2a	AB_2563340	BioLegend	405729	Mouse	Rat IgG2a, k	1:50	<15	-
IgD AF488	IA6-2	AB_11150397	BioLegend	348216	Human	Mouse IgG2a, k	1:25	<15	-
IgD AF647	IA6-2	AB_2563269	BioLegend	348228	Human	Mouse IgG2a, k	1:100	<15	-
IgM AF647	EPR5539-65-4	NA	Abcam	Ab200629	Human	Rabbit mAb	1:100	<15	-
IRF4 FITC	3E4	AB_2572538	Thermo	11-9858-82	Human, Mouse	Rat IgG1, k	1:50	<30	-
IRF4 PE	3E4	AB_2563004	Thermo	12-9858-82	Human, Mouse	Rat IgG1, k	1:50	<15	-
JOJO-1	-	-	Thermo	J11372	-	-	1:10,000	-	-
Ki-67 AF488	B56	AB_647087	BD Biosciences	558616	Human, Mouse	Mouse IgG1, k	1:50	<15	-
Ki-67 AF700	B56	AB_10611571	BD Biosciences	561277	Human, Mouse	Mouse IgG1, k	1:50	<15	-
KLRG1 AF488	2F1	AB_10898017	BD Biosciences	561619	Mouse	Hamster IgG2, k	1:50	<15	-
Laminin 1 + 2	-	AB_305933	Abcam	Ab7463	Human, Mouse	Rabbit IgG	1:100	-	-
Langerin	929F3.01	NA	Novus	DDX0362P-100	Human	Rat IgG2a	1:50	-	-
Lumican AF532	-	AB_2139484	R&D	AF2846 (Unconjugated)	Human	Goat IgG	1:50	<15	-
Lumican AF700	-	AB_2139484	R&D	AF2846 (Unconjugated)	-	Goat IgG	1:25	<15	-
Ly-6G AF488	1A8	AB_2561340	BioLegend	127626	Mouse	Rat IgG2a, k	1:50	<15	-
Lysozyme	-	AB_303050	Abcam	Ab2408	Human	Rabbit IgG	1:50	-	-
Lyve-1 eF570	ALY7	AB_2573596	Thermo	41-0443-82	Mouse	Rat IgG1, k	1:100	<15	-
Lyve-1	-	AB_355144	R&D	AF2089 (Unconjugated)	Human	Goat IgG	1:100	<15	-
MARCO	-	AB_2643767	Thermo	PA5-64134	Human	Rabbit IgG	1:25	-	-
MHC-II BV421	M5/114.15.2	AB_10900075	BioLegend	107631	Mouse	Rat IgG2b, k	1:400	-	<15
MHC-II AF647	M5/114.15.2	AB_493525	BioLegend	107618	Mouse	Rat IgG2b, k	1:600	<15	-
MHC-II AF700	M5/114.15.2	AB_493727	BioLegend	107622	Mouse	Rat IgG2b, k	1:100	<15	-
NF-H/NF-M AF488	SM1-35	AB_2750328	BioLegend	835614	Human	Mouse IgG1, k	1:50	<15	-
NK1.1 BV421	PK136	AB_10895916	BioLegend	108731	Mouse	Mouse IgG2a, k	1:50	-	<15
p53 PE	PAb 240	NA	Novus	NB200-103PE	Human	Mouse IgG1, k	1:50	<15	-
Pax5 AF647	1H9	AB_2562425	BioLegend	649704	Mouse	Rat IgG2a, k	1:100	<15	-
PD-1 BV421	29F.1A.12	AB_10900085	BioLegend	135217	Mouse	Rat IgG2a, k	1:100	-	<15
PD-1 PE	29F.1A.12	AB_1877231	BioLegend	135206	Mouse	Rat IgG2a, k	1:100	<15	-
PD-1 AF488	EH12.2H7	AB_2563594	BioLegend	329936	Human	Mouse IgG1, k	1:200	<15	-
PD-1 PE	EH12.2H7	AB_940481	BioLegend	329906	Human	Mouse IgG1, k	1:200	<15	-
PD-1 AF647	EH12.2H7	AB_940471	BioLegend	329910	Human	Mouse IgG1, k	1:200	<15	-
Podocin	JB51-33	NA	Novus	NBP2-75624	Human	Rabbit IgG	1:50	-	-
RORyt	AFKJS-9	AB_1834475	Thermo	14-6988-82	Mouse	Rat IgG2a	1:200	-	-
SiglecF PE	E50-2440	AB_394341	BD Biosciences	552126	Mouse	Rat IgG2a, k	1:100	<15	-
SiglecF AF700	1RNM44N	AB_2637126	Thermo	56-1702-80	Mouse	Rat IgG2a, k	1:50	<15	-
SIRP α AF488	P84	AB_2650815	BioLegend	144024	Mouse	Rat IgG1, k	1:50	<15	-
SIRP α AF647	P84	AB_2721300	BioLegend	144027	Mouse	Rat IgG1, k	1:200	<15	-
α SMA AF488	1A4	AB_2574460	Thermo	53-9760-80	Human, Mouse	Mouse IgG2a, k	1:500	<15	-
α SMA eF570	1A4	AB_2573631	Thermo	41-9760-82	Human, Mouse	Mouse IgG2a, k	1:300	<15	-
α SMA eF660	1A4	AB_2574461	Thermo	53-9760-82	Human, Mouse	Mouse IgG2a, k	1:500	<15	-
SPARC AF532	-	AB_355728	R&D	AF941 (Unconjugated)	Human	Goat IgG	1:50	<15	-
Syndecan-1	-	AB_442186	R&D	AF2780	Human	Goat IgG	1:50	-	-
TCR $\gamma\delta$ AF488	GL3	AB_2562771	BioLegend	118128	Mouse	Hamster IgG	1:50	<15	-
TCR $\gamma\delta$ PE	GL3	AB_313832	BioLegend	118108	Mouse	Hamster IgG	1:100	<15	-
TCR $\gamma\delta$ PE	B1	AB_1089218	BioLegend	331210	Human	Mouse IgG1, k	1:100	<15	-

Tim-3 AF532	344823	AB_2232900	R&D	MAB2365 (Unconjugated)	Human	Rat IgG2a	1:25	<15	-
Tim-3 AF647	344823	AB_2232900	R&D	MAB2365 (Unconjugated)	Human	Rat IgG2a	1:50	<15	-
Tim-4 BV421	21H12	AB_2741037	BD Biosciences	742773	Mouse	Rat IgG1, κ	1:100	-	<15
TMPRSS2	EPR3861	AB_10585592	Abcam	Ab92323	Human	Rabbit IgG	1:50	-	-
Tryptase	AA1	AB_303023	Abcam	Ab2378	Human	Mouse IgG ₁	1:50	-	-
Uromodulin FITC	10.32	AB_10012622	Novus	NBP1-50431	Human	Mouse IgG2b	1:25	<30	-
TCR Vα7.2 AF647	3C10	AB_2566335	BioLegend	351726	Human	Mouse IgG ₁ , κ	1:50	<15	-
Vimentin AF532	O91D3	NA	BioLegend	Custom	Human	Mouse IgG2a	1:200	<15	-
Vimentin AF594	O91D3	AB_2566179	BioLegend	677804	Human	Mouse IgG2a	1:300	>120	-
Vimentin AF647	O91D3	AB_2616801	BioLegend	677807	Human	Mouse IgG2a	1:600	<15	-
anti-chicken IgY FITC	-	AB_923386	Thermo	SA1-72000	-	Donkey IgG	1:200	<30	-
anti-chicken IgY AF555	-	AB_2762844	Thermo	A32932	-	Goat IgG	1:400	<15	-
anti-goat IgG AF488	-	AB_2534102	Thermo	A-11055	-	Donkey IgG	1:400	<15	-
anti-goat IgG AF555	-	AB_2535853	Thermo	A21432	-	Donkey IgG	1:300	<15	-
anti-goat IgG AF680	-	AB_2535741	Thermo	A21084	-	Donkey IgG	1:300	<15	-
anti-hamster IgG AF647	-	AB_2535868	Thermo	A-21451	-	Goat IgG	1:400	<15	-
anti-mouse IgM AF488	-	AB_2340844	Jackson ImmunoResearch	715-545-020	-	Donkey IgG	1:200	<15	-
anti-rabbit IgG AF488	-	AB_2576217	Thermo	A-11034	-	Goat IgG	1:400	<15	-
anti-rabbit IgG AF532	-	AB_2534076	Thermo	A-11009	-	Goat IgG	1:400	<15	-
anti-rabbit IgG AF555	-	AB_141784	Thermo	A-21428	-	Goat IgG	1:400	<15	-
anti-rabbit IgG AF594	-	AB_2534095	Thermo	A-11037	-	Goat IgG	1:400	>120	-
anti-rabbit IgG AF647	-	AB_2535813	Thermo	A-21245	-	Goat IgG	1:400	<15	-
anti-rabbit IgG AF700	-	AB_2535709	Thermo	A-21038	-	Goat IgG	1:400	<15	-
anti-rabbit IgG AF750	-	AB_2535710	Thermo	A-21039	-	Goat IgG	1:400	<15	-
anti-rabbit IgG AF488	-	AB_2535792	Thermo	A-21206	-	Donkey IgG	1:300	<15	-
anti-rabbit IgG AF555	-	AB_162543	Thermo	A-31572	-	Donkey IgG	1:300	<15	-
anti-rabbit IgG AF647	-	AB_2536183	Thermo	A-31573	-	Donkey IgG	1:400	<15	-
anti-rabbit IgG AF488	-	AB_2572214	Thermo	Z-25302	-	Goat Fab ₂	-	<15	-
anti-rabbit IgG AF532	-	AB_2736945	Thermo	Z-25303	-	Goat Fab ₂	-	<15	-
anti-rabbit IgG AF555	-	AB_2736950	Thermo	Z-25305	-	Goat Fab ₂	-	<15	-
anti-rabbit IgG AF594	-	AB_2736956	Thermo	Z-25307	-	Goat Fab ₂	-	>120	-
anti-rabbit IgG AF647	-	AB_2736962	Thermo	Z-25308	-	Goat Fab ₂	-	<15	-
anti-rat IgG AF647	-	AB_141778	Thermo	A-21247	-	Goat IgG	1:400	<15	-
anti-rat IgG AF647	-	AB_2340694	Jackson ImmunoResearch	712-605-153	-	Donkey IgG	1:200	<15	-
anti-sheep IgG AF680	-	AB_2535755	Thermo	A-21102	-	Donkey IgG	1:300	<15	-

Table S2. IBEX panels for human organs.
Lymph node (Manual IBEX): 38 parameters, 9 cycles

Cycle	Marker	Clone	Conjugate	Isotype	Vendor	Catalog Number	Dilution
1	Hoechst	-	-		Biotium	40046	1:5000
	CD20	L26	AF488	Mouse IgG2b, κ	eBioscience	53-0202-82	1:100
	CD10	FR4D11	PE	Mouse IgG1, κ	Caprico Biotechnologies	103924	1:25
	CD3	UCHT1	AF594	Mouse IgG1, κ	BioLegend	300446	1:50
	BCL2	100	AF647	Mouse IgG1	BioLegend	658705	1:25
	Collagen IV	Polyclonal rabbit IgG	Goat anti-Rabbit IgG AF700	Rabbit IgG Goat IgG	Abcam Thermo	Ab6586 A-21038	1:50 1:250
2	IgD	IA6-2	AF488	Mouse IgG2a, κ	BioLegend	348215	1:25
	CD23	EBVCS-5	AF532	Mouse IgG1, κ	BioLegend	Custom	1:25
	CD138	MI15	PE	Mouse IgG1, κ	BioLegend	356503	1:200
	CD3	UCHT1	AF594	Mouse IgG1, κ	BioLegend	300446	1:100
	BCL6	K112-91	AF647	Mouse IgG1, κ	BD Biosciences	561525	1:10
	CD31	WM59	AF700	Mouse IgG1, κ	BioLegend	303133	1:25
3	HLA-DR	L243	AF488	Mouse IgG2a, κ	BioLegend	307619	1:100
	CD21	Bu32	AF532	Mouse IgG1, κ	BioLegend	NA, Custom	1:600
	CD1c	L161	PE	Mouse IgG1, κ	BioLegend	331505	1:50
	CD3	UCHT1	AF594	Mouse IgG1, κ	BioLegend	300446	1:100
	CD163	GH1/61	AF647	Mouse IgG1, κ	BioLegend	333620	1:100
	CD11c	B-Ly6	AF700	Mouse IgG1, κ	BD Biosciences	561352	1:25
4	CD8	SK1	AF488	Mouse IgG1, κ	BioLegend	344716	1:50
	FOXP3	236A/E7	eF570	Mouse IgG1, κ	eBioscience	41-4777-82	1:50
	CD3	UCHT1	AF594	Mouse IgG1, κ	BioLegend	300446	1:50
	CD25	M-A251	AF647	Mouse IgG1, κ	BioLegend	356127	1:50
5	CD4	RPA-T4	FITC	Mouse IgG1, κ	Thermo	58-0049-41	1:25
	SPARC	Goat IgG	AF532	Goat IgG	R&D	AF941	1:25
	PD-1	EH12.2H7	PE	Mouse IgG1, κ	BioLegend	329905	1:200
	CD3	UCHT1	AF594	Mouse IgG1, κ	BioLegend	300446	1:50
	CD69	FN50	AF647	Mouse IgG1, κ	BioLegend	310918	1:25
	CD38	HIT2	AF700	Mouse IgG1, κ	BioLegend	303524	1:25
6	ICOS	C398.4A	AF488	Hamster IgG	BioLegend	313514	1:25
	CXCL13	Goat IgG	AF532	Goat IgG	R&D	AF801 (Unconjugated)	1:25
	IRF4	IRF4.3E4	PE	Rat IgG1, κ	BioLegend	646403	1:50
	CD3	UCHT1	AF594	Mouse IgG1, κ	BioLegend	300446	1:50
	CD68	KP1	AF647	Mouse IgG1, κ	Santa Cruz	sc-20060	1:100
	Ki-67	B56	AF700	Mouse IgG1, κ	BD Biosciences	561277	1:50
7	CD44	IM7	AF532	Rat IgG2b, κ	BioLegend	Custom	1:50
	CD35	E11	PE	Mouse IgG1, κ	BioLegend	333406	1:800
	CD3	UCHT1	AF594	Mouse IgG1, κ	BioLegend	300446	1:100
	Vα7.2	3C10	AF647	Mouse IgG1, κ	BioLegend	351726	1:50
8	SMA-alpha	1A4	AF488	Mouse IgG2a, κ	Thermo	53-9760-80	1:100
	CD106	STA	PE	Mouse IgG1, κ	BioLegend	305805	1:50
	CD3	UCHT1	AF594	Mouse IgG1, κ	BioLegend	300446	1:50
9	Clec9a	8F9	AF488	Mouse IgG2a, κ	BioLegend	Custom	1:25
	Lyve-1	Polyclonal goat IgG	AF532	Goat IgG	R&D	AF2089 (Unconjugated)	1:100
	CD45	F10-89-4	PE-IF594	Mouse IgG2a, κ	Caprico Biotechnologies	1016185	1:100
	CD3	UCHT1	AF594	Mouse IgG1, κ	BioLegend	300446	1:50
	DC-SIGN	9E9A8	AF647	Mouse IgG2a, κ	BioLegend	330112	1:50

Spleen (Manual IBEX): 25 parameters, 4 cycles

Cycle	Marker	Clone	Conjugate	Isotype	Vendor	Catalog Number	Dilution
1	Hoechst	-	-		Biotium	40046	1:5000
	CD20	L26	AF488	Mouse IgG2b, κ	eBioscience	53-0202-82	1:200
	CD21	Bu32	AF532	Mouse IgG1, κ	BioLegend	NA, Custom	1:400
	Glycophorin AF555	EPR8200	AF555	Rabbit IgG	Abcam Abcam	Ab218372 Ab269820	1:300
	CD68	KP1	iF594	Mouse IgG1, κ	Caprico Biotechnologies	1064135	1:50
	CD54	HA58	AF647	Mouse IgG1, κ	BioLegend	353114	1:100
	Fibrinogen	Polyclonal sheep IgG Polyclonal donkey IgG	Donkey anti- sheep IgG AF680	Sheep IgG Donkey IgG	Abcam Thermo	Ab118533 A-21102	1:200 1:400
2	CD15	MMA Donkey anti-mouse IgM	Donkey anti- mouse IgM AF488	Mouse IgM, κ Donkey IgG	BD Biosciences Jackson Immunoresearch	347420 715-545-020	1:50 1:200
	CD163	GH1/61	AF532	Mouse IgG1, κ	BioLegend	Custom	1:200
	CD138	MI15	PE	Mouse IgG1, κ	BioLegend	356503	1:200
	HLA-DR	L243	iF594	Mouse IgG2a, κ	Caprico Biotechnologies	1032136	1:100
	CD49a	TS2/7	AF647	Mouse IgG1, κ	BioLegend	328310	1:200
	CD11c	B-Ly6	AF700	Mouse IgG1, κ	BD Biosciences	561352	1:25
3	CD8	SK1	AF488	Mouse IgG1, κ	BioLegend	344716	1:25
	Vimentin	O91D3	AF532	Mouse IgG2a, κ	BioLegend	Custom	1:200
	CD31	WM59	PE	Mouse IgG1, κ	BioLegend	303106	1:100
	CD3	UCHT1	iF594	Mouse IgG1, κ	AAT Bioquest	103400C0	1:50
	CD4	RPA-T4	AF647	Mouse IgG1, κ	BioLegend	300520	1:100
	Ki-67	B56	AF700	Mouse IgG1, κ	BD Biosciences	561277	1:25
4	CD61	Y2/51	FITC	Mouse IgG1, κ	Miltenyi	130-098-682	1:25
	SPARC	Goat IgG	AF532	Goat IgG	R&D	AF941	1:50
	SMA-alpha	1A4	eF570	Mouse IgG2a, κ	Thermo	41-9760-82	1:300

	CD45	F10-89-4	iF594	Mouse IgG2a, κ	Caprico Biotechnologies	1016138	1:100
	CD44	IM7	AF647	Rat IgG2b, κ	BioLegend	103018	1:200
	Lumican	Polyclonal goat IgG	AF680	Goat IgG	R&D Thermo	AF2846 A-20188	1:25

Human Liver (Manual IBEX): 22 parameters, 4 cycles

Cycle	Marker	Clone	Conjugate	Isotype	Vendor	Catalog Number	Dilution
1	Hoechst	-	-		Biotium	40046	1:5000
	Keratin 7	W16155A	AF488	Rat IgG2a, κ	BioLegend	601605	1:50
	ASS1	Polyclonal rabbit IgG Polyclonal donkey IgG	Donkey anti-rabbit IgG AF555	Rabbit IgG Donkey IgG	Abcam Thermo	Ab170952 A31572	1:100 1:300
	CD34	4H11	iF594	Mouse IgG1	AAT Bioquest	103400C0	1:50
	CD54	HA58	AF647	Mouse IgG1, κ	BioLegend	353114	1:50
	Lyve-1	Polyclonal goat IgG Polyclonal donkey IgG	Donkey anti-goat IgG AF555	Goat IgG Donkey IgG	R&D Thermo	AF2086-SP A21084	1:400 1:300
	2	HLA-DR	L243	AF488	Mouse IgG2a, κ	BioLegend	307619
CD163		GH1/61	AF532	Mouse IgG1, κ	BioLegend	99486	1:100
CD138		MI15	PE	Mouse IgG1, κ	BioLegend	356503	1:200
CD68		KP1	iF594	Mouse IgG1, κ	Caprico Biotechnologies	1064136	1:100
Fibrinogen		Polyclonal sheep IgG Polyclonal donkey IgG	Donkey anti-sheep IgG AF680	Sheep IgG Donkey IgG	Abcam Thermo	Ab118533 A-21102	1:100 1:300
3		CD8	SK1	AF488	Mouse IgG1, κ	BioLegend	344716
	B-Tubulin 3	TUJ1	AF532	Mouse IgG2a, κ	BioLegend	Custom	1:100
	Glutamine Synthetase	Polyclonal rabbit IgG Anti-rabbit Fab	AF555	Rabbit IgG	Abcam Thermo	Ab49873 Z-25303	1:100
	CD3	UCHT1	iF594	Mouse IgG1, κ	Caprico Biotechnologies	1053134	1:50
	CD4	RPA-T4	AF647	Mouse IgG1, κ	BioLegend	300520	1:50
	Ki-67	B56	AF700	Mouse IgG1, κ	BD Biosciences	561277	1:25
4	αSMA	1A4	AF488	Mouse IgG2a, κ	Thermo	53-9760-80	1:600
	CD44	IM7	AF532	Rat IgG2b, κ	BioLegend	Custom	1:50
	CD49a	TS2/7	PE	Mouse IgG1, κ	BioLegend	328303	1:500
	CD45	HI30	AF594	Mouse IgG2a, κ	BioLegend	304060	1:100
	Vimentin	O91D3	AF647	Mouse IgG2a, κ	BioLegend	677807	1:600

Lymph node (Automated IBEX): 24 markers, 6 cycles

Cycle	Marker	Clone	Conjugate	Isotype	Vendor	Catalog Number	Dilution
1	Hoechst	-	-		Biotium	40046	1:5000
	CD20	L26	AF488	Mouse IgG2b, κ	eBioscience	53-0202-82	1:100
	CD34	4H11	iF594	Mouse IgG1	AAT Bioquest	103400C0	1:25
	CD54	HA58	AF647	Mouse IgG1, κ	BioLegend	353114	1:50
	Lyve-1	Polyclonal goat IgG		Goat IgG	R&D	AF2086-SP	1:400
	Collagen IV	Polyclonal rabbit IgG		Rabbit IgG	Abcam	Ab6586	1:50
2	Collagen IV	Donkey anti-rabbit IgG	AF488	Donkey IgG	Thermo	A-21206	1:200
	Lyve-1	Donkey anti-goat IgG	AF555	Donkey IgG	Thermo	A-21432	1:200
	CD68	KP1	iF594	Mouse IgG1, κ	Caprico Biotechnologies	1064135	1:50
	CD49a	TS2/7	AF647	Mouse IgG1, κ	BioLegend	328310	1:50
3	CD21	Bu32	AF488	Mouse IgG1, κ	BioLegend	98148	1:100
	CD35	E11	PE	Mouse IgG1, κ	BioLegend	333406	1:200
	HLA-DR	L243	iF594	Mouse IgG2a, κ	Caprico Biotechnologies	1032136	1:50
	CD163	GH1/61	AF647	Mouse IgG1, κ	BioLegend	333620	1:50
4	CD8	SK1	AF488	Mouse IgG1, κ	BioLegend	344716	1:25
	PD-1	EH12.2H7	PE	Mouse IgG1, κ	BioLegend	329906	1:50
	CD3	UCHT1	iF594	Mouse IgG1, κ	Caprico Biotechnologies	1053135	1:50
	CD4	RPA-T4	AF647	Mouse IgG1, κ	BioLegend	300520	1:25
5	Desmin	Y66	AF488	Rabbit IgG	Abcam	Ab185033	1:50
	CD31	WM59	PE	Mouse IgG1, κ	BioLegend	303106	1:100
	CD45	F10-89-4	iF594	Mouse IgG2a, κ	Caprico Biotechnologies	1016136	1:100
	CD138	MI15	AF647	Mouse IgG1, κ	BioLegend	356524	1:100
6	CD44	IM7	AF488	Rat IgG2b, κ	BioLegend	103016	1:50
	CD94	DX22	PE	Mouse IgG1, κ	BioLegend	305506	1:50
	Vimentin	O91D3	AF594	Mouse IgG2a, κ	BioLegend	677804	1:300
	αSMA	1A4	eF660	Mouse IgG2a, κ	Thermo	53-9760-82	1:200

Jejunum (Automated IBEX): 24 markers, 6 cycles

Cycle	Marker	Clone	Conjugate	Isotype	Vendor	Catalog Number	Dilution
1	Hoechst	-	-		Biotium	40046	1:5000
	EpCAM	9C4	AF488	Mouse IgG2b, κ	BioLegend	324210	1:300
	CD106	STA	PE	Mouse IgG1, κ	BioLegend	305806	1:50
	CD34	4H11	iF594	Mouse IgG1	AAT Bioquest	103400C0	1:25
	CD54	HA58	AF647	Mouse IgG1, κ	BioLegend	353114	1:50
	Lysozyme	Polyclonal rabbit IgG		Rabbit IgG	Abcam	Ab2408	1:50
	Lyve-1	Polyclonal goat IgG		Goat IgG	R&D	AF2089	1:100
	2	Lysozyme	Donkey anti-rabbit IgG	AF488	Donkey IgG	Thermo	A-21206
Lyve-1		Donkey anti-goat IgG	AF555	Donkey IgG	Thermo	A-21432	1:200

	CD68	KP1	iF594	Mouse IgG1, κ	Caprico Biotechnologies	1064135	1:50
	CD49a	TS2/7	AF647	Mouse IgG1, κ	BioLegend	328310	1:50
3	Tubulin3	TUJ1	AF488	Mouse IgG2a, κ	BioLegend	801203	1:50
	CD31	WM59	PE	Mouse IgG1, κ	BioLegend	303106	1:100
	HLA-DR	L243	iF594	Mouse IgG2a, κ	Caprico Biotechnologies	1032136	1:50
	Cytokeratin	AE1/AE3	eF660	Mouse IgG1	Thermo	50-9003-82	1:50
	CD8	SK1	AF488	Mouse IgG1, κ	BioLegend	344716	1:25
4	PD-1	EH12.2H7	PE	Mouse IgG1, κ	BioLegend	329906	1:50
	CD3	UCHT1	iF594	Mouse IgG1, κ	Caprico Biotechnologies	1053135	1:50
	CD4	RPA-T4	AF647	Mouse IgG1, κ	BioLegend	300520	1:25
	IgA2	A9604D2	AF488	Mouse IgG1, κ	SouthernBiotech	9140-30	1:400
5	CD138	MI15	PE	Mouse IgG1, κ	BioLegend	356503	1:100
	CD45	F10-89-4	iF594	Mouse IgG2a, κ	Caprico Biotechnologies	1016136	1:100
	IgA1	B3506B4	AF647	Mouse IgG1, κ	SouthernBiotech	9130-31	1:400
	CD44	IM7	AF488	Rat IgG2b, κ	BioLegend	103016	1:100
6	αSMA	1A4	eF570	Mouse IgG2a, κ	Thermo	41-9760-82	1:200
	Vimentin	O91D3	AF647	Mouse IgG2a, κ	BioLegend	677807	1:300

Skin (Automated IBEX): 19 markers, 5 cycles

Cycle	Marker	Clone	Conjugate	Isotype	Vendor	Catalog Number	Dilution
1	Hoechst	-	-		Biotium	40046	1:5000
	CD34	4H11	iF594	Mouse IgG1	AAT Bioquest	103400C0	1:25
	CD54	HA58	AF647	Mouse IgG1, κ	BioLegend	353114	1:50
	Lumican	Polyclonal goat IgG		Goat IgG	R&D	AF2846	1:200
	EpCAM	Polyclonal rabbit IgG		Rabbit IgG	Abcam	Ab71916	1:50
2	Lumican	Donkey anti-goat IgG	AF488	Donkey IgG	Thermo	A-11055	1:400
	EpCAM	Donkey anti-rabbit IgG	AF555	Donkey IgG	Thermo	A-31572	1:200
	CD68	KP1	iF594	Mouse IgG1, κ	Caprico Biotechnologies	1064135	1:50
	CD49a	TS2/7	AF647	Mouse IgG1, κ	BioLegend	328310	1:50
	Langerin	929F3.01		Rat IgG2a	Novus	DDX0362P-100	1:50
3	HLA-DR	L243	AF488	Mouse IgG2a, κ	BioLegend	307620	1:50
	CD117	104D2	PE	Mouse IgG1, κ	BioLegend	313204	1:50
	CD3	UCHT1	iF594	Mouse IgG1, κ	Caprico Biotechnologies	1053135	1:25
	Langerin	Donkey anti-Rat IgG	AF647	Donkey IgG	Jackson Immuno Research	712-605-153	1:200
	CD44	IM7	AF488	Rat IgG2b, κ	BioLegend	103054	1:50
4	CD31	WM59	PE	Mouse IgG1, κ	BioLegend	303106	1:100
	CD45	F10-89-4	iF594	Mouse IgG2a, κ	Caprico Biotechnologies	1016136	1:100
	CD138	MI15	AF647	Mouse IgG1, κ	BioLegend	356524	1:100
	Keratin 14	Poly9060		Chicken IgY	BioLegend	906004	1:50
	Keratin 10	DE-K10	AF488	Mouse IgG1, κ	Novus	NBP2-54402AF488	1:200
5	Keratin 14	Goat anti-Chicken IgY	AF555	Goat IgG	Invitrogen	A32932	1:400
	Vimentin	O91D3	AF594	Mouse IgG2a, κ	BioLegend	677807	1:300
	αSMA	1A4	eF660	Mouse IgG2a, κ	Thermo	41-9760-82	1:50

Kidney (Automated IBEX, FFPE): 16 markers, 5 cycles

Cycle	Marker	Clone	Conjugate	Isotype	Vendor	Catalog Number	Dilution
1	Hoechst	-	-		Biotium	40046	1:5000
	Cathepsin L	204101		Rat IgG2a	R&D	MAB-9521	1:50
	CD10	Polyclonal goat IgG		Goat IgG	R&D	AF1182	1:200
	Podocin	JB51-33		Rabbit IgG	Novus	NBP2-75624	1:50
	Cytokeratin	AE1/AE3	AF488	Mouse IgG1	Thermo	53-9003-82	1:50
	CD34	QBEND-10	PE	Mouse IgG1, κ	Thermo	MA1-10205	1:50
	CD68	KP1	iF594	Mouse IgG1, κ	Caprico Biotechnologies	1064135	1:25
	αSMA	1A4	eF660	Mouse IgG2a, κ	Thermo	50-9760-82	1:50
2	CD10	Donkey anti-goat IgG	AF488	Donkey IgG	Thermo	A-11055	1:400
	Podocin	Donkey anti-rabbit IgG	AF555	Donkey IgG	Thermo	A-21432	1:400
	CD66b	G10F5	iF594	Mouse IgM, κ	Caprico Biotechnologies	1075139	1:25
	Cathepsin L	Donkey anti-rat IgG	AF647	Rat IgG2a	Jackson Immunoresearch	712-605-153	1:100
3	CD15	MMA		Mouse IgM, κ	BD	347420	1:25
	CD15	Polyclonal	AF488	Donkey IgG	Jackson Immunoresearch	715-545-020	1:200
	Donkey anti-mouse IgM AF488						
	ACE2	Polyclonal, Custom conjugate	AF555	Goat IgG	R&D Abcam	AF933 Ab269820	1:50
	SPARC	Polyclonal, Custom conjugate	iF594	Goat IgG	R&D AAT Bioquest	AF941 1230	1:50
TMPRSS2	EPR3861, Custom conjugate	AF647	Rabbit IgG	Abcam	Ab92323 Ab269823	1:50	

4	Lumican iF594	Polyclonal goat IgG Custom conjugate	iF594	Goat IgG	R&D AAT Bioquest	AF2846 1230	1:200
5	Uromodulin	10.32	FITC	Mouse IgG2b	Novus	NBP1-50431	1:25
	Glycophorin	EPR8200, Custom conjugate	AF555	Rabbit IgG	Abcam Abcam	Ab218372 Ab269820	1:300
	Syndecan-1	Polyclonal, Custom conjugate	iF594	Goat IgG	R&D AAT Bioquest	AF2780 1230	1:50
	Vimentin	O91D3	AF647	Mouse IgG2a, κ	BioLegend	677807	1:200

Please see original IBEX publication for additional panels including the following mouse tissues:
lymph node, spleen, thymus, lung, small intestine, and liver:

<https://doi.org/10.1073/pnas.2018488117>.

Table S3. Recommendations for optimal antibody and fluorophore pairing for IBEX panel design.

Ex/Em Max (nm)	Fluorophore	Inactivation Method	Dim (1)-Brightest (5)	IBEX Method	Special Considerations
350/461	Hoechst 33342	-	5	Both	Preferred fiducial for registration and nuclear segmentation Overcomes high autofluorescence in this channel, especially in human tissues
410/455	Pacific Blue	<15 minutes	1	Manual (tested)	Dim, limited availability of direct conjugates Use Hoechst 33342 in this channel
405/421	Brilliant Violet 421	<15 minutes + Light	4	Manual (tested)	Use Hoechst 33342 in this channel High autofluorescence in human tissues Light inactivation is tedious for large areas
405/510	Brilliant Violet 510	<15 minutes + Light	1	Manual (tested)	Use Hoechst 33342 in this channel High autofluorescence in human tissues Light inactivation is tedious for large areas
490/525	AF488	<15 minutes	4	Both	Excellent fluorophore for IBEX Wide availability of direct conjugates, labeling kits, and secondary antibodies Pair with moderate to highly expressed markers
490/525	FITC	<30 minutes	3	Both	Prioritize AF488 over FITC conjugated antibodies
532/554	AF532	<15 minutes	3	Manual	Suitable fluorophore for manual IBEX Limited availability of direct conjugates and secondary antibodies Pair with highly expressed markers and be mindful of spectral overlap between AF555/PE/eF570 channel
533/544	JOJO-1	-	4	Manual	Avoid and use Hoechst 33342 as nuclear marker and fiducial instead
555/580	AF555	<15 minutes	3	Both	Excellent fluorophore for IBEX Wide availability of direct conjugates, labeling kits, and secondary antibodies Pair with moderate to highly expressed markers and be mindful of spectral overlap with AF532 channel
546/585	eF570	<15 minutes	3	Both	Good fluorophore for IBEX Limited availability of direct conjugates, labeling kits, and secondary antibodies Pair with moderate to highly expressed markers and be mindful of spectral overlap with AF532 channel
488-561/565	PE	<15 minutes	5	Both	Prioritize AF555 and eF570 conjugates Prone to photobleaching but can be paired with dim markers Be mindful of spectral overlap with AF532 channel and non-specific binding to tissues
587/603	iF594	<15 minutes	4	Both	Excellent fluorophore for IBEX Limited availability of direct conjugates, labeling kits, and secondary antibodies
590/617	AF594	-	5	Both	Can be paired with a structural marker and used as fiducial or placed in the final IBEX cycle Avoid and use Hoechst 33342 as fiducial and iF594 instead
560/645	eF615	-	4	Both	Can be paired with a structural marker and used as fiducial or placed in the final IBEX cycle Avoid and use Hoechst 33342 as fiducial and iF594 instead Limited availability of direct conjugates, labeling kits, and secondary antibodies
650/665	AF647	<15 minutes	5	Both	Excellent fluorophore for IBEX Wide availability of direct conjugates, labeling kits, and secondary antibodies Pair with dim to moderately expressed markers
633/669	eF660	<15 minutes	4	Both	Excellent fluorophore for IBEX Limited availability of direct conjugates, labeling kits, and secondary antibodies Pair with dim to moderately expressed markers
679/702	AF680	<15 minutes	3	Manual	Suitable fluorophore for manual IBEX, cannot be separated from adjacent channels on THUNDER Limited availability of direct conjugates and secondary antibodies Pair with highly expressed markers
702/723	AF700	<15 minutes	1	Manual	Suitable fluorophore for manual IBEX Limited availability of direct conjugates and secondary antibodies Pair with highly expressed markers and place in Cycles 1-4
749/775	AF750	<15 minutes	3	Automated	Suitable fluorophore for automated IBEX on THUNDER but signal greatly diminished with AFC, in general avoid Limited availability of direct conjugates and secondary antibodies

Table S4. Estimated costs for IBEX implementation.

<p>Tissue Grossing and Processing</p> <ul style="list-style-type: none"> • Reagents and consumables for 100 samples <\$5,000 • Tools for embedding/processing for 100 samples <\$1,000 • Cryostat (Leica CM1950) or equivalent, available in most core facilities ~\$45,000 • Rotary microtome (Leica, RM2255) or equivalent, available in most core facilities <\$20,000 • Stereomicroscope and illuminator <\$5,000 	<p>Manual and Automated IBEX</p>
<p>Immunolabeling and microscopy</p> <ul style="list-style-type: none"> • Leica TCS SP8 X confocal microscope or equivalent, highly variable \$500,000-700,000 • PELCO BioWave Pro microwave and SteadyTemp Pro, optional (incubate at 37°C) ~\$31,000 • ~\$4 per antibody per run (2 µg in 400 µl), scales with complexity of panels and number of samples 	<p>Manual IBEX</p>
<p>Immunolabeling and microscopy</p> <ul style="list-style-type: none"> • Leica THUNDER microscope or equivalent, dependent on configuration \$175,000-200,000 • ARIA Fluidics Device <\$15,000 • Imaging chamber, vacuum, and heater from Warner instruments <\$5,000 • Additional accessories (triggering cables) <\$100 • ~\$4 per antibody per run (2 µg in 400 µl), scales with complexity of panels and number of samples 	<p>Automated IBEX</p>
<p>Software and system requirements for image processing</p> <ul style="list-style-type: none"> • Imaris and Imaris File Converter (x64, version 9.5.0), variable depending on bulk pricing and bundling with other licenses, \$5,000-10,000 per license • Imaris Viewer \$0 • Custom Imaris Extension \$0 • System requirements for image processing, highly variable \$4,000-30,000 <ul style="list-style-type: none"> ○ MacBook Pro 2.3 GHz 8-Core i9 with 32 GB memory \$4,000, scaled to multiple nodes on a high-performance cluster (>\$5,000 per node) for batch processing ○ HP Z8 G4 Workstation or equivalent \$16,000-21,000 	<p>Manual and Automated IBEX</p>